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ABSTRACT 
 
Cardiovascular health is a major determinant of quality of life and mortality, 
especially in older adulthood. With the world’s oldest population increasing at expedited 
rates, challenges from cardiovascular conditions and its implications are spawning. 
Although it is well known that dyslipidemia may lead to cardiac events, less is known 
about the effects on cognitive and physical function in older adults. Epidemiological 
studies show that optimizing current preventive strategies even at older ages may 
reduce the incidence of cardiovascular comorbidity (e.g. hypertension, stroke) and 
increase quality of life. Determining the association between lipoproteins and cognitive 
and functional performance in older adults may help develop interdisciplinary 
interventions designed to maintain independence longer and improve the overall quality 
of life.  
The current dissertation contains two studies examining serum lipoproteins, 
specifically total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), 
triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) in older adults in 
relation to cognitive and functional outcomes. The first study examined the association 
between lipoproteins and cognitive performance in a cognitively normal older adult 
population. Results showed an association between low levels of TG and higher 
composite cognitive scores (CCS), but this association disappeared when 
apolipoprotein ε4 allele (APOE ε4 allele) was adjusted for in the model. High levels of 
viii 
 
HDL-C were also associated with the CCS and this association remained significant 
even after adjusting for APOE ε4 allele. Furthermore, these associations were only 
significant among women. High HDL-C remained linked with visuospatial function and 
attention and working memory even after adjusting for APOE ε4 allele. Further 
moderation analysis indicated that the association between TGs, HDL-C and cognitive 
performance was moderated by the APOE ε4 allele. Stratification by carriers and non-
carriers of the ε 4 allele indicated that the previous association was only significant for 
non-carriers.  
The second study of this dissertation is a longitudinal analysis, which explored 
the association between TC, LDL-C, TG and HDL-C and physical function. Random 
effects analysis was used to assess whether lipoprotein levels affect subsequent 
change in physical function. All models were adjusted for baseline age, sex, education, 
and perceived current economic situation, cardiovascular risk factors and comorbidity 
inclusive of cognitive disability. Results showed that lower levels of TC and HDL-C had 
cross-sectional associations with more ADL disability but not longitudinally, and higher 
levels of TG were related to better grip function. Moderation analysis of the previous 
significant association indicated that only cognitive disability moderated the cross-
sectional association between TC and for ADLs. Further stratification showed that the 
association was only pertinent for participants with cognitive disability. Independent of 
cardiovascular risk factors and an extensive list of comorbidities, older adults living in 
the community with higher levels of TC, TG and HDL-C were associated with better 
physical function outcomes. Lipid patterns in older adults may be indicative of physical 
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function and may serve clinicians as a tool to compress morbidity in older adults and 
help them maintain independence and a high quality of life for as long as possible. 
In conclusion, lipid levels in older adults play an important role in maintaining 
cognitive and physical function into older ages, thus maintaining a good quality of life.   
Higher HDL-C seemed to be the lipid associated with maintaining cognitive function, 
while TC dominated the association with physical function.
 
  
 1 
 
 
CHAPTER 1: INTRODUCTION 
 
Cardiovascular health is a major determinant of quality of life and mortality, 
especially in older adulthood. The American Heart Association estimates that 43.7 
million Americans over the age of 60 currently have some form of cardiovascular 
disease (CVD) and these numbers are expected to increase1. Projections for the year 
2030 indicate that about 72.8 million adults in the United States will be over the age of 
652,3. With the world’s oldest population increasing at expedited rates, challenges from 
cardiovascular conditions and its implications are rising. Two important anticipated 
health challenges with the increasing older adult population is maintaining good 
cognitive and physical functioning.  Today, 8% white, 11% African-American and 12% 
Hispanics Medicare beneficiaries have dementia4. With estimates of 5.1 million adults 
older than 65 with Alzheimer’s dementia4 and almost 16 million with some form of 
disability5 occurrence of these conditions is worrisome especially since these seem to 
develop “silently” from subclinical vascular components. A study found that among older 
adults, 37% had subclinical cardiovascular disease6. The need to determine the 
contributing factors associated with these devastating diseases is imperative to prevent 
or delay these conditions and the socioeconomic implications for future generations.  
The association between aging and the development of cardiovascular pathology 
is primarily due to arterial aging7,8. Research indicates that arterial aging gives rise to 
the development of a chronic inflammatory process that leads to atherosclerosis and 
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subsequent complications such as CVD7,9-11, cognitive deterioration12,13, and functional 
decline13,14. The combination of CVD, cognitive and/or physical limitations in older 
adults is of great public health importance as it can lead to faster rates of dependence, 
increases in healthcare costs, and overall decreases in the quality of life.  
Research shows many influences involved in the process of vascular aging and 
the senescence of the endothelium15,16. One such factor is dyslipidemia, which has 
been repeatedly found to not only contribute for the progression of arterial aging but 
also CVD8,17-19. Dyslipidemia is defined as a disorder in lipoprotein metabolism in which 
there is either an overproduction or a deficiency of lipoproteins, usually presented as 
elevation of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), 
triglycerides (TG) or a decrease in high-density lipoprotein cholesterol (HDL-C)20. 
Although some may argue that lipoprotein levels, versus aortic or carotid intima-media 
thickness, may reflect only a snapshot of vascular aging16, properly assessing routine 
clinical biomarkers as proxies for vascular aging may prove to be a valuable and more 
economic easily accessible tool. Thus understanding the associations between lipids 
and health outcomes (e.g. cognitive and physical function) in older adults may provide 
the foundations to develop interdisciplinary interventions to maintain independence 
longer and improve the overall quality of life.  
Studies with lipids have historically used conceptual models that have tended to 
be only bio-physiological and seldom inclusive of the wide range of variables needed to 
correctly determine the associations. A framework of biopsychosocial factors is needed 
to ultimately determine, if as a whole, they influence outcomes. Wilson and Cleary21 
proposed the Health-Related Quality of Life Conceptual Model, which incorporates 
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basic clinical science with social science measures to evaluate health outcomes 
according to underlying existing health conditions with the goal of describing health and 
critical concepts that are in the causal pathway.  
Figure 1 shows the Health-Related Quality of Life Conceptual Model of patient 
outcomes by Wilson and Cleary (1995) as it is applied to the research performed in this 
dissertation. It provides basic understandings of the role of lipoproteins in cognitive and 
physical function among older adults. The model includes biological function measures 
(e.g., lipid levels), integrates symptoms and functional status measures as mid-factors, 
with measures of health perceptions and overall quality of life. This conceptual model 
considers biological and physiological factors, which are routinely used in clinical 
practice, as basic determinants of health and inter-relates them with psychosocial 
measures often used in behavioral research. The purpose of the model is to understand 
the overall associations of factors of interest, with the ultimate goal of finding methods to 
improve the quality of life. In figure 1 the original model has been modified by showing 
the category of functional status split in two boxes as (a) physical function and (b) 
cognitive function. The blue colored boxes with bold frames show the sections and 
variables included in this dissertation.   
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To understand the association between lipoproteins and health outcomes in 
aging, it is important to first understand that lipoproteins are essential molecules the 
body needs to function properly. As defined, lipoproteins are molecules composed of a 
protein, or apoprotein, in contact with a lipid, cholesterol and/or triglyceride22. Proteins, 
also known as polypeptides, are made up of a linear chain of amino acids23. Lipids are 
non-polar organic solvents composed of fatty acids made up of a hydrocarbon chain 
that ends in a carboxylic acid group23,24.  
 
Figure 1. Modified health-related quality of life conceptual model of patient outcomes 
from Wilson & Cleary (1995).
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There are different types of circulating lipoproteins, categorized according to size 
and density; some are polar hydrophilic peripheral proteins and some are non-polar 
hydrophobic able to penetrate the lipid bilayer25.  They can be divided in two major 
groups: cholesterol and triglyceride transporters. Cholesterol is essential in the aging 
process for cell division, brain and central nervous function as well as for numerous 
biological immune processes such as the production of hormones, vitamin D, and cell 
repair26. Cholesterol carrying lipoproteins are divided into LDL-C, or β-lipoproteins and 
HDL-C, or α-lipoproteins. LDL-C lipoproteins are commonly referred as “bad 
cholesterol” because they are the most involved in the formation of atherosclerosis, and 
HDL-C are often referred as the “good cholesterol” as they are known to be protective of 
CVD. Triglyceride (TG) lipoproteins can be intermediate density lipoproteins (IDL), very 
low density lipoproteins (VLDL), also known as pre-β-lipoproteins or chylomicrons, the 
largest and lowest in density among all plasma soluble lipoproteins24,27. TC is calculated 
by the sum of HDL-C plus LDL-C and twenty percent TG levels28.  
Normal clinical ranges for lipoproteins vary by age, sex, and ethnicity29-31. Table 1 
provides lipid reference values for the general adult population as stipulated by the 
Adult Treatment Panel III report32,33. When these lipoproteins are outside the estimated 
ranges (above desired levels), there is an increased risk of cardiovascular disease34,35. 
Specific cardiovascular risk can be calculated based on established age, race, and sex 
specific risk equations36,37. In this dissertation, only TC, LDL-C, TG and HDL-C are 
explored as these are the routinely examined lipids in clinical practice. 
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Lipoproteins, Cognitive and Functional Outcomes 
Little is known about the association between lipoproteins, cognitive and physical 
function. Many of the same contributing factors for CVD continue to directly and actively 
influence cognitive function in older adults. It is not completely understood why there are 
inherent changes in cognition as people age. Changes in fluid intelligence such as 
decreased memory, less reasoning ability, more difficulty making new associations, 
lower ability to solve new problems, and perceptual speed and memory decline happen; 
yet, crystalized intelligence such as vocabulary and knowledge of general information 
increases38. Studies have related higher levels of TC and LDL-C among older adults 
with improved cognitive abilities and some suggest these may even protect cognition39-
Table 1. Normal Range of Lipoprotein Levels According to the ATP III Report*. 
Lipoprotein Normal/Desirable Borderline High High Very High 
TC <200 mg/dL 
(<5.2mmol/l) 
200-239 mg/dL 
(5.2- 6.2 mmol/l 
≥240 mg/dL 
(6.2mmol/l) 
n/a 
LDL-C <100 mg/dL optimal 
(<2.6 mmol/l) 
 
100-129 mg/dL  
(2.6-3.4 mmol/l) 
Near or above 
optimal 
130-159 mg/dL 
(3.4-4.1 mmol/l) 
160-189 mg/dL 
(4.1-4.9 mmol/l) 
≥190 mg/dL 
(>4.9 mmol/l) 
TG < 150 mg/dL  
(<1.7 mmol/l) 
150-199 mg/dL 
(1.8-2.2 mmol/L) 
200-499 mg/dL (2.3-
5.6 mmol/L) 
>500 mg/dL 
(>5.7 mmol/L) 
HDL-C <40 mg/dL is low and ≥60 mg/dL High/desirable 
(<1.0 mmol/l is low) and (≥1.5 mmol/l is High/desirable) 
 
Note. TC=Total Cholesterol, LDL-C=Low Density Lipoprotein cholesterol, TG=triglycerides, HDL-C=High Density 
Lipoprotein cholesterol, mg=milligrams, dL=deciliter, mmol=millimol.*Executive Summary of the Third Report of the 
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III), 2001 
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42 and physical function43,44. Little research has been found associating TG to cognitive 
and/or functional outcomes among older adults. One study reported higher TG levels 
linked to worse cognitive performance in older adults45. A more recent study was able to 
detect a significant decline in vocabulary with higher TG levels over a 10-year period46. 
Higher levels of HDL-C are not only associated with CVD protection1,47 but have also 
been associated with better cognitive performance45,48,49.  
 
Factors Affecting Lipoprotein Levels in Older Adults  
Lipoprotein levels in older adults tend to be influenced by factors such as 
genetics22,50; ethnicity 51; medications and/or treatment response52-55; lifestyle and 
environmental factors (e.g. sedentary lifestyle10,56); malnutrition57,58; frailty59, and/or the 
existence of comorbid conditions (e.g. cancer, chronic diseases)57,60.  
Genetics play an important role in lipid metabolism. Although not extremely 
common in the general population, genetic variations such as homozygous familial 
hypercholesterolemia22,50, a genetic mutation in the LDL-C receptor, apolipoprotein B or 
the protein convertase subtillisin kexin type 9 gene61, or mutations in other genes or 
acquired defects can be responsible for lipid anomalies62,63. Most notably, the 
association between lipids and the apolipoprotein E (APOE) gene located on 
chromosome 19 has been reported. There are three common allele variants of this 
protein: ε2, ε3 and ε4 depending on the number of amino acids and their positions, and 
they vary by ethnicity64. APOE ε3 allele is the most common, but APOE ε4 allele is 
present in about a quarter of the general population and is associated with higher levels 
of TC and LDL-C65,66. Studies have shown that some isoforms of APOE (i.e., carriers of 
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the ε2 and/or ε3 allele show lower levels of TC and LDL-C and higher HDL-C) may 
inhibit the atherosclerotic process by its anti-oxidant and anti-inflammatory properties 
and can assist HDL-C in the cholesterol efflux thus lowering plasma cholesterol levels 
47,64-68. APOE carriers of at least one ε4 allele (ԑ2/ԑ4, ԑ3/ԑ4, or ԑ4/ԑ4) (APOE ε4) do not 
have these protective factors and have been associated with higher TC and LDL-C 
levels placing them at higher risk of myocardial infarctions and coronary heart disease 
than ε3 carriers46,65. Other genetic determinants identified through genome-wide 
association studies have identified several genes responsible for low and high levels of 
HDL-C69.  
Chronic conditions such as cardiovascular comorbidity (e.g., hypertension and 
stroke), diabetes, and depression are important intervening factors in the association 
between lipoproteins and aging56. These health conditions disrupt lipoprotein 
metabolism and are all significant determinants for quality of life having direct physical 
and social effects among elders. These factors are accounted for in the second study of 
this dissertation. While sex hormones also have an evident role in the lipid process70,71, 
their influence may not be as significant among post-menopausal adults. Therefore, 
hormonal influence on lipids is not considered in this dissertation.  
Response to cholesterol treatment (e.g. statins) diminishes with age52, may 
aggravate comorbid conditions such as diabetes by increasing levels of hemoglobin A1c 
(HbA1c) and fasting glucose72 and/or may cause important adverse side effects73,74. 
Secondary hyperlipidemia may also result from some commonly prescribed drugs such 
as steroids, progestin, hypoglycemics such as rosiglitazone, certain antipsychotic 
medications, commonly used antihypertensive medication and diuretics such as 
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hydrochlorothiazide and older generation beta-blockers54,55. The second study of this 
dissertation accounts for some of these medications.  
In summary, many factors can increase or decrease lipoprotein levels; and all of 
them appear to be associated to abnormalities in synthesis, transport or degradation of 
the specific particles. Accounting for as many of these variables in studies looking at the 
association between lipoproteins and health outcomes is of great importance to properly 
interpret the results. 
 
Lipoproteins, Cardiovascular Disease and Aging 
As people age the risk of dyslipidemia increases; however, it is still unclear 
exactly why this occurs20. Middle aged adults and those in early older adulthood are 
known to have an increased risk of dyslipidemia, specifically hypercholesterolemia75, 
which explains the strong relationship with increased risk of coronary heart disease and 
stroke after the age of 6520,75,76. Adults with cardiovascular risk factors in midlife, such 
as hyperlipidemia, and previous cardiovascular events are at increased risk of cognitive 
associated problems such as cognitive decline and dementia77-83. Analysis from the 
ONTARGET and TRANSCEND studies found an association between baseline mini-
mental state exam scores <24/30 and 35% increased risk of having cardiovascular 
events; the authors suggest that perhaps cognitive impairment is just a marker of end-
organ damage from vascular factors80. Others have found similar associations82. 
Contrary, among older adults, the literature indicates that lower levels of some 
lipids may be related to lower cognitive function39,40,45,48,49,84,85 and difficulties in physical 
function and/or performing activities of daily living86,87. Despite important advancements, 
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the aging literature is far from reaching consensus in the exact relationship between 
lipoproteins, cognitive function and functional abilities. A summary of the latest research 
findings between TC, LDL-C, TG, and HDL-C and aging follows. 
 
Lipoproteins and Aging 
Total Cholesterol. Existing literature in cholesterol is complex and studies are 
filled with contradictory results when it comes to older adults. In the year 2000, 
decrease trends of TC were observed for both men and women over age 60; however, 
women maintained higher levels than men88. Research shows that in early and mid-life, 
adults able to sustain low TC levels have lower cardiovascular comorbidity and longer 
life expectancy1. However, in older adults, low TC levels have been associated with 
higher mortality89-94, whereas increased levels are associated with reduced mortality95. 
But an association of lipids with mortality seems to have ethnic variations. Detrimental 
lipid levels do not appear to correlate with mortality among Hispanics92. Hispanics are 
known to have more cardiovascular risk factors than Whites96 but have one of the 
lowest mortality from cardiovascular events97. Some have reported this overall mortality 
advantage in older Hispanics as the ‘Hispanic Paradox’98.  
Low-density Lipoprotein Cholesterol. A limited number of studies have looked 
at LDL-C particles and longevity, but have found a positive association between low 
LDL-C and longer life99-101. LDL-C makes up 60-70% of TC in serum and is the main 
lipoprotein associated with risk of CVD and the most targeted lipoprotein in clinical 
practice102-106. Studies show an increase of LDL-C as people age20,107. Recent studies 
indicate that LDL-C increases progressively after the age of 20, in men it reaches a 
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plateau around 50-60 years and in women between 60-7076. In contrast, a recent study 
looking at 2,944 healthy Korean women to determine the effect of age on atherogenicity 
of LDL-C found mean levels of LDL-C increase by age groups up to age 59, but for 
groups in ages higher than 60 (ages of 60-79) LDL-C levels and particle size 
decreased108. However, in the United States, it is estimated that more than half (58.2%) 
of those over 65 years of age have high LDL-C levels109, increasing the risk of CVD and 
mortality for this older cohort. In a study of dyslipidemia among Hispanics, the authors 
found significant differences in the levels LDL-C across background groups (e.g. Central 
American, Cuban, Dominican, Mexican and South Americans)29. Overall, high LDL-C 
was found in 36% of all Hispanics; Cubans and South Americans had the higher 
prevalence rates with 44.5 and 39.8 percent respectively, while Dominicans had the 
lowest prevalence at 31.6 percent29. Further studies of lipoproteins with different ethnic 
groups is needed to fully understand the lipid distribution in a population with various 
racial and ethnic groups.  
High-density Lipoprotein Cholesterol. HDL-C measures the cholesterol 
content within alpha-HDL in plasma, but it does not differs the type of particle or size47. 
Research has shown that larger particle sizes of HDL-C have been associated with 
people without hypertension or CVD100. Larger particle size and lower particle 
concentrations have also been found among long-lived individuals99,110, but in the 
Leiden Longevity Study this association on HDL particle phenotype was only found 
among women and was dependent on TG levels99. Studies have shown that HDL-C 
levels differ between men and women, with men usually presenting lower levels than 
women45,85,88,111. Among Hispanic individuals, women have been reported to have lower 
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levels of HDL-C than males29. HDL-C in general is well associated with cardiovascular 
events47 even in patients taking statins112. Low levels of HDL-C have been known to be 
a major risk factor for cardiovascular disease47,88,104,106,112-114, stroke115 and mortality 
among older individuals110,113. However, resent research among the Framingham 
Offspring Study in adults older than 50 with more than 2 consecutive measures of HDL-
C and no previous CVD found no association between HDL-C and cardiovascular 
events116. 
Triglycerides. As people age, TG levels seem to increase. This increase peaks 
in middle age for men and then decline, while in women the increase is maintained 
throughout life and manifests more in those taking estrogens20,76. Changes in 
hormones, dietary patterns, and metabolism have been associated with change in 
levels, but it is poorly understood why TG change with age. Over a quarter of adults 
older than 20 years have TG levels ≥ 150mg/dL but less than 3% actually take 
treatment56. Research from National Health and Nutrition Examination Survey 
(NHANES), shows that in adults 20-74 years of age, TG levels have increased by 6 
mg/dL (0.07mmol/L) from 1988-1994 to 1999-2002117. Overall females have been found 
to have lower levels of TG than males101,117. A recent study found lower levels of TGs in 
the offspring of long-lived siblings than those of controls, and this again seemed 
significant for women only101. With the exception of Blacks, minorities in general, 
particularly Hispanics, have an increase prevalence of hypertriglyceridemia51,97. In 
NHANES, Mexican-Americans had higher levels of TG than non-Hispanic Blacks and 
non-Hispanic Whites117.  
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Lipoproteins and Cognitive Function 
Factors affecting cognitive function in older adults are still not well understood. 
While cognitive abilities (e.g., memory, speed, and attention) linked to fluid intelligence 
tend to decline with age, cognitive abilities (e.g., vocabulary and general information 
linked to crystallized intelligence) tend to increase and remain stable with age38. 
Recently, cardiovascular research has attempted to unfold the links between some well-
known risk factors for CVD and these cognitive abilities (e.g. fluid and crystalized 
intelligence). Research looking at cardiovascular factors such as exercise, smoking, 
dyslipidemia, and hypertension has found associations with changes in cognitive 
functioning78,118-121. However, literature in the association between cognitive 
performance and lipoproteins is fairly recent, scarce and inconclusive for older adults. 
Most published studies have focused on risk of cognitive decline or dementia as 
outcomes and have not evaluated the actual cognitive performance as the primary 
result. In addition, most have measured cognition with brief, non-specific tests such as 
the Mini-Mental State Examination (MMSE); only few have used specific cognitive 
domains. Despite these limitations, several trends have been observed. 
Total Cholesterol. The association between TC and cognitive performance 
seems driven as a function of age. Studies have found that overall high TC in midlife is 
detrimental to cognitive performance42,122-124. In contrast, several studies agree that 
higher levels of TC in older age correlate with improved cognitive function39,40 and some 
have suggested that it may serve as a protective factor in old age41,84,125,126. A review 
study showed that overall, high midlife TC increased the risk of cognitive decline and 
dementia; but at older ages, high TC either had no association with cognitive function or 
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showed a protective relationship122,123. Van Vliet and colleagues suggest four possible 
explanations for why high midlife TC levels are a risk factor for late life cognitive decline 
and why high TC in older ages may be protective: high TC in midlife may be detrimental 
for cognition because: (1) cholesterol has a negative influence on deposition of beta-
amyloid plaques in the brain and (2) has a direct effect on increasing CVD. In contrast, 
high TC may be protective of cognitive function in late life due to: (1) the direct effects of 
cholesterol on the maintenance of brain function (amongst which are synapse formation 
and maintenance) and (2) low TC levels in late life likely reflect general ill health, and 
may then be seen as an epiphenomenon122,123. A cross-sectional analysis of The 
Framingham Heart Study using adults 55-88 years old from the years 1974-1978 found 
lower TC levels (<180 mg/dL) associated with worse cognitive performance measured 
through a composite score as well as in individual cognitive domains39. Investigators 
from the Women’s Health and Aging Study II also found that among older women, there 
was a dose-response association between TC levels and the Purdue Pegboard, higher 
levels of TC yielded better scores127. Yet others find no association at older ages128-132. 
This inconsistency of results is mostly due to different designs, populations studied (e.g. 
racial and/or ethnic differences), methods used in both the analysis of TC, and the 
battery of neuropsychological tests used. 
Low-density Lipoprotein Cholesterol. Higher levels of LDL-C have been 
associated with some forms of fluid intelligence such as better memory performance in 
middle age, particularly for mental manipulation and rapid mental processing85,132. 
Higher LDL-C has also yield better immediate recall in some studies48,132. An analysis 
performed in The Longitudinal Aging Study Amsterdam (LASA) in the Netherlands, 
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conducted every three years on men and women between 55-85 years of age found a 
positive threshold effect at levels ≤ 4.2 and 3.8 mmol/L respectively for LDL-C on 
general cognition performance and information processing speed48. Lower levels of 
LDL-C have been associated with lower general cognitive performance48 and have also 
been linked to lower fluid intelligence measured through processing speed in another 
study133. Yet others have been unable to find any association between LDL-C and 
cognition49,129,134-136.  
High-density Lipoprotein Cholesterol. Higher levels of HDL-C are not only 
associated with CVD protection1,47 but have also been associated with better cognitive 
performance45,48,49.  Interestingly, this protective effect of HDL-C seems to be sex driven 
predominating among women. High HDL-C levels yielded better maintenance of verbal 
ability (crystalized intelligence) in women over the age of 65, but not in men; better 
perceptual speed performance (fluid intelligence) was seen in women before age 65 
only85. Among a sample of nonagenarians, (adults 90 years of age or older), low HDL-C 
was associated with poor scores in the Spanish version of the MMSE; but once 
covariates were adjusted in the model, the effect disappeared137. A similar association 
was seen by The Longitudinal Aging Study Amsterdam. However, when looking at 
specific cognitive domains, a positive association was observed between high HDL-C 
and better performance on immediate recall (Auditory Verbal Learning Test) and 
information processing speed in time-adjusted models but only immediate recall 
remained significant over time48. Despite the mentioned findings, many recent 
longitudinal studies have not been able to find any association between higher levels of 
HDL-C and any improvement in cognition129,132,134,136. It may be speculated that 
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differences in methodological approaches to these longitudinal studies such as diverse 
demographic characteristics of the samples (e.g. large age ranges, sex-specific 
samples, ethnic differences) may not capture significant lipid associations. The duration 
of the studies and the times lipids were collected may also have an impact on the lack 
of findings. If lipids in a longitudinal study were only measured once, this may 
underestimate the association of HDL-C or other lipids and cognitive function. 
Additionally, the types of cognitive measures included, the number of occasions 
participants tested, and the interval of time between the testing occasions may add to 
the limitations. 
Triglycerides. Limited research has been found associating TG to cognitive 
function among older adults. A study among the oldest-old Chinese found that high TG 
in this group of older adults was associated with better cognitive function measured 
using the MMSE138. Contrariwise, an earlier study was able to detect a significant 
decline in vocabulary with higher TG levels over a 10-year period46. Atzmon and 
colleagues reported higher TG levels linked to worse cognitive performance in older 
adults45. The Swedish Adoption/Twin Study85 found lower triglycerides related to better 
cognitive outcomes in women. Yet, others found no correlations between TG and the 
MMSE139. 
Apolipoprotein ԑ4 Allele and Cognition. Among older adults, research on the 
association between APOE ε4 allele and cognition has been centered on the increased 
risk of dementia and/or cognitive decline, less on cognitive function. Recent research 
has recognized that the APOE ε4 allele plays an important role in cognitive outcome 
differences140-142. Furthermore, within group differences have been observed on 
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different cognitive tests. A recent meta-analysis looking at 77 studies on cognitively 
healthy adults found that carriers of APOE ε4 allele performed worse on measures of 
episodic memory, executive functioning, and overall global cognitive ability than non-
carriers of the APOE ε4 allele143. An earlier meta-analysis found that despite small 
group differences, compared to non-carriers of the ε4 allele, carriers had statistically 
significant worse performance on global cognitive function and episodic memory and 
executive function scores140. However, it is less clear the role APOE plays on cognitive 
performance among older adults. Research performed on adults older than 65 years of 
age free of dementia found that carriers of the APOE ε4 allele have more difficulty and 
decline more rapidly in semantic memory and perceptual speed but not in working 
memory or visuospatial skills142. 
APOE regulates lipid transport cholesterol and homeostasis in the brain144 and 
the ε4 allele is known to increase the risk of CVD in part by being associated with pro-
atherogenic TC, LDL-C levels and higher VLDL-cholesterol-to-HDL-C ratio46,65,144. The 
atherosclerotic process leads to cardiovascular pathology which is associated with 
cerebral hypoperfusion; microvascular hemorrhages, extracranial athero-embolisms and 
small vessel disease77,145,146, all which increase the risk of cognitive 
dysfunction40,79,121,147-153. Thus, it is expected that APOEε4 will modify the association 
between lipoproteins and cognitive function in some extent. 
 
Lipoproteins and Functional Outcomes 
Cardiovascular disease is among the top 15 conditions that cause 
disability1,86,154. Disability is the inability or difficulty to carry out activities of daily living 
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(ADL) and problems performing instrumental activities of daily living (IADL)155. When 
ADL and/or IADLs become more effortful for older adults, health gradually declines, 
quickly leading to dependency, decreased quality of life, and increase health service 
utilization156.  The prevalence of functional disabilities in those with CVD has been 
estimated around 23%; yet, independent of established CVD, some independent 
vascular risk factors have been associated with disability as well86.  
Some studies have associated low levels of TC44 and low HDL-C157 in older ages 
with mobility limitations and disability43,44,157. Recent studies from populations in Ireland 
and Italy, have found high levels of HDL-C associated with reduced risk of functional 
impairment even after accounting for other lifestyle-based CVD risk factors (e.g., 
smoking, exercise) and cardiovascular diseases such as stroke or coronary heart 
disease86,158. However, Welmer et al. (2014) observed an opposite trend in community 
dwelling older adults (60 years or older) enrolled in the Confucius Hometown Aging 
Project of China; among them, higher TC was related with functional limitations and 
dependence87. Much is still to be known about the relationship between lipids, functional 
limitations and disability, especially at advanced ages.  
 
Aims 
Research is just beginning to unravel the associations between lipids and 
cognitive and physical function. The literature is fairly recent, scarce and inconclusive. 
But this area of research is also crucial for understanding the effects of lipoproteins on 
cognitive and physical health, which can guide in developing effective interventions to 
maintain health in the aging population. Studies show that dyslipidemia may lead to 
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cardiac events and progressive deterioration of daily functional activities86,154,159,160 and 
potentially contribute to cognitive deterioration85,136,161-163. However, most studies have 
not evaluated cognitive performance in the old as the primary outcome and have 
measured cognition mainly with brief, non-specific tests such as the MMSE. 
Additionally, functional limitations and disability, which are often collapsed as one, are 
rarely used as the primary outcome. Moreover, little is known about these topics in 
understudied populations. No previous study had looked at lipids and cognitive function 
in older adults who reside in the Czech Republic, nor had any study looked at the 
longitudinal association between lipids and physical function among Latinos. 
As people are living longer, the concern for disease burden in older ages 
becomes increasingly important, especially when it comes to cardiovascular disease. 
Lipid disruption seems to be at the core of most cardiovascular pathology, thus the need 
to address their association with health outcomes in older adult populations. This 
dissertation anticipates contributing to the existing literature by improving the 
understanding of the association between serum lipoproteins and health outcomes by 
investigating the association between specific lipoproteins such as TC, LDL-C, TG, and 
HDL-C in relation to cognitive and physical function outcomes in adults over the age of 
60. It is hypothesized that high levels of TC, LDL-C and HDL-C and low levels of TG in 
adults over the age of 60 will be associated with better cognitive and physical function.  
The aim of this dissertation is addressed through two separate research studies, 
each with specific aims. Study one, looks specifically at the association between TC, 
LDL-C, TG and HDL-C and cognitive function in cognitively normal adults over the age 
of 60 residing in the Czech Republic. Study two, looks at the association between TC, 
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LDL-C, TG and HDL-C and physical function across three study waves between 2005 
and 2010 in a population sample of adults over the age of 60 residing in Costa Rica. 
This population has not been previously examined in the literature in relation to the 
association of lipoproteins and physical function. 
 
Study 1 
Aim 1. The first aim was to examine the association between TC, LDL-C, TG and 
HDL-C and cognitive performance (measured as a composite cognitive score and 
separate cognitive domains: verbal and nonverbal memory; attention and working 
memory; language; visuospatial function; and executive function).  
Hypothesis 1. Based on previous findings which suggest significant associations 
between lipoproteins and cognitive performance 39,41,42, it was hypothesized that high 
levels of TC, LDL-C and HDL-C and low levels of TG would be associated with better 
cognitive function (higher composite cognitive scores and higher scores in each 
individual cognitive domain: nonverbal and verbal memory; visuospatial function; 
executive function; attention and working memory; and language). 
Aim 2. The second aim was to investigate whether age, sex and/or APOE ԑ4 
allele status moderated any statistically significant association between each 
independent lipoprotein (TC, LDL-C, TG and HDL-C) and the composite cognitive 
scores in model 1. 
Hypothesis 2. It was hypothesized that age, sex and/or APOE ԑ4 allele status 
would moderate any statistically significant association between each independent 
lipoprotein and the composite cognitive score. It was hypothesized that the association 
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between each independent lipoprotein and cognitive performance would be more 
pronounced in older participants. Specifically, it was also hypothesized that the 
association between lipoproteins and cognitive performance would differ between men 
and women with the expectation that the association would be more prevalent among 
women. It was also hypothesized that the association between lipoproteins and 
cognitive performance would be significant only among non-carriers of at least one 
APOE ε4 risk allele. 
 
Study 2 
Aim 1. The main purpose of this study was to determine if baseline measures of 
independent lipoproteins TC, LDL-C and HDL-C are associated with change in physical 
function taking into account demographics, cardiovascular risk factors and comorbidity 
in adults over the age of 60 participating in the Costa Rican Longevity and Healthy 
Aging Study (CRELES). Physical function measured as (a) disability (ADL and IADL 
disability) and (b) functional limitations (e.g. grip strength; equilibrium/balance; walking). 
Hypothesis 1. It was hypothesized that those older adults with lower baseline 
levels of TC, LDL-C and HDL-C and high levels of TG would have worse physical 
function decline (more disability and functional limitations) over the study period even 
after adjusting for demographics and possible confounders.  
Aim 2. The second aim was to investigate whether sex and/or cognitive disability 
moderated any statistically significant association between baseline lipoproteins (TC, 
LDL-C, TG and HDL-C) and change in physical function over time.  
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Hypothesis 2. It was hypothesized that sex and/or cognitive disability would 
moderate any statistically significant association between each independent lipoprotein 
and physical function. Specifically, it was also hypothesized that the association 
between lipoproteins and physical function would differ between men and women; with 
the expectation that physical function decline would be more prevalent among women. 
It was also hypothesized that the association between lipoproteins and physical function 
would be significant only among participants with cognitive disability. 
This dissertation was approved and exempted by the Institutional Review Board 
of the University of South Florida on May15, 2015. Portions of the first study used in this 
dissertation have been published before in the Journal of International 
Psychogeriatrics164 and are being used with permission of Cambridge Press. 
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CHAPTER 2: STUDY 1: CHOLESTEROL AND COGNITIVE PERFORMANCE 
AMONG COMMUNITY VOLUNTEERS FROM THE CZECH REPUBLIC 
 
Abstract 
 
 Disruption of lipids, particularly high total cholesterol (TC), high low-density 
lipoprotein cholesterol (LDL-C), high triglycerides (TG) and low high-density lipoprotein 
cholesterol (HDL-C) correlates with cardiovascular disease and may also be associated 
with worse cognitive function in middle age adults, and particularly among women and 
apolipoprotein ε4 allele carriers (ԑ2/ԑ4, ԑ3/ԑ4, or ԑ4/ԑ4) (APOE ε4). This study looks at 
the association of six well-established cognitive domains and a composite cognitive 
score (CCS) and TC, LDL-C, TG, and HDL-C in older adults from the Czech Republic (n 
= 112) over the age of 60 with Mini-Mental State exam scores ≥24. Ordinary least 
squares regressions models were conducted. Model 1 adjusted for age, sex, education, 
and depressive symptoms and model 2 additionally adjusted for APOE ε4 allele. 
Furthermore, a moderation analysis by age, sex and the presence of at least one APOE 
ε4 allele was carried out. Results showed better CCS associated with lower levels of TG 
(p=.036) and higher levels of HDL-C (p=.008); the latter remained significant even after 
adjustment for APOE ε4 allele (p=.018). High HDL-C levels were associated with better 
visuospatial function (p=.043) and attention/working memory (p=.044) even after 
adjustment of the APOE ε4 allele. Moderation analysis indicated APOE ε4 allele as 
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theory significant moderator in the association between better CCS and low TG and 
high HDL-C among non-carriers only. Neither age nor sex moderated the effect of the 
association between any of the lipoproteins and CCS. Low TG and high HDL-C were 
the main lipoproteins associated with cognitive performance, with results somewhat 
more pronounced among women and non-carriers of the APOE ε4 allele. Further 
research is needed to first, test if maintaining lipoproteins at optimum recommended 
levels into older ages does maintain cognitive function. Second, future studies should 
strive to explore if boosting HDL-C levels positively changes cognitive function in aging 
populations. 
 
Introduction 
Dyslipidemia is a common medical problem that tends to occur with age. It 
increases the risk of adverse coronary events, especially after the age of 6520,75,76 and 
has been found to be associated with poor cognitive function78,118-121,124 as well as an 
increased risk of cognitive decline and dementia77-83. Previous research on the 
association between lipoproteins and cognitive function (e.g. measures of fluid and 
crystalized intelligence) has been limited, mostly performed among middle age adults 
and often from pharmacological intervention studies78,79,121,132,165-170. Few have 
evaluated cognitive performance only among older adults and the results have been 
inconsistent39,40,45,48,49,84,85,127-129,171,172.  
Recent investigations have observed correlations between high levels of total 
cholesterol (TC) and improved cognitive function in older adults39,40,126.  Previous 
studies have even suggested that high TC levels may be associated with better 
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cognition in advanced old age41,84,122,123,125,126. Furthermore, a recent study suggested 
that the association between TC and cognition is U-shaped; indicating that both low and 
high levels of TC were associated with lower cognitive scores173. However, some 
studies have observed no association between lipoproteins and cognitive 
performance128-132. Given these inconsistent findings, further research with older adults 
is needed to understand the association between TC and cognitive function. 
Lower levels of low-density lipoprotein cholesterol (LDL-C) have also been 
associated with lower general cognitive performance48 and lower processing speed 
among older adults133. An earlier study conducted in postmenopausal women with 
established CVD found high levels of LDL-C related to worse cognitive performance171. 
Yet other investigators have not found any links between LDL-C and cognition49,129,136, 
leaving room for additional research to support or refute the association between LDL-C 
and cognition. 
Higher levels of high-density lipoprotein cholesterol (HDL-C) are not only cardio-
protective; they also appear associated with better cognitive performance45,48,49; 
especially among women. High HDL-C levels have been specifically linked with better 
verbal ability in women only85. Additionally, baseline HDL-C have shown a positive 
association with immediate recall and speed of processing in both men and women48. 
However, many longitudinal studies have found no association between HDL-C and 
cognition129,132,134,136,171.   
Fewer studies have found significant associations between triglycerides (TG) and 
cognitive function.  Earlier studies found that among older adults, those with low TG 
levels performed better on the Mini-Mental State Exam45. Particularly, within women, 
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lower TG were related to better cognitive outcomes85, while those with high TG showed 
a decline in vocabulary over a 10-year period46. However, a recent study found that high 
normal TGs (mean level of TG in the 95th percentile equal to 2.15 mmol/l) were 
associated with a decreased risk of cognitive impairment independent of cognitive 
function138. Yet, others found no links between TG and the MMSE129,139,171. 
Lipid levels differ between males and females76,174, thus sex differences in the 
association between lipoproteins and cognitive function has also been observed. 
Despite the lack of sex-stratified studies, a trend seems to exist indicating that the 
association between lipids and cognitive function may be stronger among women. For 
example, in the Swedish Adoption/Twin Study lipid levels were more indicative of 
cognitive aging in women than in men, with higher HDL-C and lower triglycerides 
related to better cognitive outcomes in women85. In women-only studies, high 
concentrations of LDL-C and TC were both associated with better memory132 and better 
psychomotor speed127. More sex-stratified studies are needed to determine if the 
association between lipids and cognitive performance does vary between older males 
and females, and if so what are the intervening factors in this association. 
Finally, variations in apolipoprotein ε4 allele (i.e., ԑ2/ԑ4, ԑ3/ԑ4, or ԑ4/ԑ4 vs. 
variants without any ԑ4) (APOE ԑ4 allele) have been associated with cognitive function. 
A meta-analysis showed that despite small effect sizes, those carriers of the APOE ε4 
allele had lower cognitive function, including episodic memory and executive function140. 
A study over 3.2 years found a greater decline in memory among carriers of the APOE 
ε4 allele than non-carriers133. Although little is known about the association between 
APOE ε4 allele and its impact on lipoproteins and cognitive function, some studies have 
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associated APOE ε4 allele with lipid levels and cognition. De Frias et al (2007) found 
that higher TC was associated with greater decline in recognition only among carriers of 
the APOE ε4 allele. Yasuno et al (2012) reported that higher HDL-C was related to 
better cognition only for non-carriers of the APOE ԑ4 allele gene. Similarly, a study 
among older adults from New York reported that the associations found between high 
TC and LDL-C and better cognitive function only held for APOE ε4 non-carriers126. 
Therefore, further investigation of the role of being APOE ԑ4 carrier vs. non-carrier in 
the association between lipoproteins and cognitive performance in older ages seems 
warranted. If differences in the association exist based on variants of the APOE ԑ4 
allele, perhaps future gene-targeted studies are needed to determine clear associations 
that can lead to gene-specific interventions in the future. 
 
Research Aims 
The current study has two main aims. The first aim explores the association 
between independent lipoproteins and cognitive performance in older adults. The 
second aim examines a possible moderation effect of age, sex and APOE ԑ4 allele on 
the association between lipids and cognitive performance. 
Aim 1. The first aim was to examine the association between TC, LDL-C, TG and 
HDL-C and cognitive performance (measured as a composite cognitive score and 
separate cognitive domains: verbal and nonverbal memory; attention and working 
memory; language; visuospatial function; and executive function).  
Hypothesis 1. Based on previous findings which suggest significant associations 
between lipoproteins and cognitive performance39,41,42, it was hypothesized that high 
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levels of TC, LDL-C and HDL-C and low levels of TG would be associated with better 
cognitive function (higher composite cognitive scores and higher scores in each 
individual cognitive domain: nonverbal and verbal memory; visuospatial function; 
executive function; attention and working memory; and language). 
Aim 2. The second aim was to investigate whether age, sex and/or APOE ԑ4 
allele status moderated any statistically significant association between each 
independent lipoprotein (TC, LDL-C, TG and HDL-C) and the composite cognitive 
scores in model 1.  
Hypothesis 2. It was hypothesized that age, sex and/or APOE ԑ4 allele status 
would moderate any statistically significant association between each independent 
lipoprotein and the composite cognitive score. Specifically, it was also hypothesized that 
the association between lipoproteins and cognitive performance would differ between 
men and women; with the expectation that the association would be more prevalent 
among women. It was also hypothesized that the association between lipoproteins and 
cognitive performance would be significant only among non-carriers of at least one 
APOE ε4 risk allele. 
 
Methods 
 
Study Sample 
This cross-sectional study uses pooled data from participants recruited between 
2005 and 2012 from the Memory Clinic at University Hospital Motol in Prague, Czech 
Republic participating in a longitudinal study. Participants in this study (a) came to the 
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memory clinic due to concern about their memory expressed by themselves or by a 
relative, (b) were recruited from the University of the Third Age, or (c) were relatives or 
caregivers of patients with MCI or AD. All participants underwent a thorough 
neuropsychological examination and provided medical history.  
Figure 2 shows the sample included in this study. There were 215 adults with 
biomarker data ±60 days from the administration of the neuropsychological battery. 
After restricting the sample to those with Mini Mental State Examination (MMSE) scores 
≥24, age ≥ 60 years, and information about education, 112 adults remained for analysis. 
A cut off of 24 on the MMSE was established based on criteria frequently used in 
clinical practice175,176.  
 
 
Figure 2. Study One Flow Diagram. 
Note. MMSE = Mini-Mental State Exam; SD=Standard Deviation 
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Out of 215 participants, 54 had MMSE scores below 24; 50 were under the age 
of 60, and 2 were missing education variable. Those excluded from the sample were on 
average a year older, with one less year of education than the general sample and most 
were females. Due to the high education levels of the sample, no education effects or 
bias is anticipated. The study was approved by the institutional ethics committee from 
the Memory Clinic at 2nd Faculty of Medicine, Charles University and University 
Hospital Motol in Prague, Czech Republic and written informed consent was obtained 
from all subjects participating in the study. The database obtained for this study was 
completely anonymous (name and other identifiers were removed). 
 
Neuropsychological Battery 
 The psychometric battery included the Mini-Mental State Exam which was used 
to screen for cognitive impairment, with a cut point greater or equal to 24 which is 
recommended for clinical practice175, and the assessment of the following domains:  
Visuospatial. Visuospatial function was evaluated with the Rey-Osterrieth 
Complex Figure Test – the Copy condition ROCFT-C177-179. This test, specifically the 
copy condition was developed to assess functions of the brain such as attention and 
concentration, fine-motor coordination, visuospatial perception, and organizational 
skills177,179,180. Although some age effects (e.g. older adults do not perform as well as 
their younger counterparts), some sex effects (males obtain higher scores than females) 
and education/IQ effects have been reported, it is a commonly used visuospatial test179. 
For the copy condition the participant is handed a piece of paper and a pencil and is told 
that he/she would be presented with a figure. A stimulus card with a geometric figure is 
presented in front of them and they are instructed to copy the figure to the best of their 
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ability. The participant is told there is no time limit to complete the task; however, the 
psychometrist starts timing as soon as the oral instructions are completed and keeps 
track of the respondent’s executions of the figure. When the participant completes the 
figure, the stop time is recorded and the stimulus card removed. A specific protocol for 
the scoring system exists with raw scores ranging from 0.0 to 36.0; low scores are 
indicative of compromised or reduced visuo-perceptual and visuomotor skills180.  
Nonverbal Memory. Nonverbal memory, or visual memory, was evaluated using 
the Immediate Recall condition of the Rey-Osterrieth Complex Figure Test (ROCFT-
R)177,178. The ROCFT-R is assessed immediately after the copy portion of the ROCFT is 
performed. The psychometrist removes the stimulus and the copy and the participant is 
asked to reproduce the image they just copied from memory177. This task evaluates 
nonverbal memory which is related to the hippocampus and associated regions in the 
right hemisphere180. The scoring protocol for the immediate recall also range from 0.0 to 
36.0; low scores are indicative of compromised or reduced visuospatial recall ability, or 
non-verbal memory180. 
Verbal Memory. Verbal memory was tested using the Auditory Verbal Learning 
Test (AVLT)181-183 trials 1-6, the AVLT-30 minute recall trial and the free and cued 
selective reminding test (FCSRT) or Total Recall Score184,185. Detailed instructions for 
each of the tests were given to each participant before each trial. The AVLT used in this 
study is the Czech version186. The AVLT is a neuropsychological test that determines 
the participant’s ability to encode, associate, store, and retrieve verbal information 
previously encoded as well as the maximum amount of information able to retrieve from 
that learned in the trials187,188. In the AVLT trials 1-6 test, the participant hears a list of 
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15 semantically unrelated nouns read at a rate of one per second. When all the words 
have been read, the participant is asked to recall as many words from the list as 
possible. The psychometrist records all the words recalled correctly and any intrusions 
and/or perseverations (any additional words recalled that were not read or any repeated 
words).  This is carried out 5 consecutive times with the order of the presentation and 
the words fixed across the trials. Then the examiner presents a second list of 15 new 
words; this time the participant is only allowed to recall them in one attempt. Then 
immediately the participant is asked to remember as many words as possible from the 
first list. The AVLT- 30 minute is when the participant is asked to recall the trial 
previously administered after 30 minutes to measure retention. Scoring for the AVLT is 
complex and calculations for the Czech version of this test used in the ongoing 
longitudinal study can be found elsewhere186. The recalled part (total recall) of the test 
after 30 minutes has a maximum score of 15. In this study, a modified version of the 
FCSRT called Enhanced Cued Recall (ECR test in Czech validated version) was 
used188,189. The FCSRT consists of asking the participant to search for a card, which 
contains line drawings of 4 objects and is asked to identify the one belonging to the 
category named by the psychometrist. After the item is correctly identified the card is 
removed. If it is incorrectly chosen, the error is corrected. This is done 12 additional 
times for a total of 16 items and/or possible points188. The total verbal memory score is 
calculated as the mean of the sum of the AVLT trials 1-6, AVLT-30 minute recall trial 
and the FCSRT188. 
Executive Function. Despite the disagreement in the literature as to how to best 
measure executive function190, for this study it was measured with the Digit Symbol 
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Substitution Test (DSST)191. The DSST is used as a measure of attention, speed of 
processing, motor speed, visual scanning and memory in many protocols192, especially 
among older adults as no education effects have been seen for younger or older 
adults193. Even though DSST is often included under the attention domain, it clearly 
overlaps with executive function194. For the purpose of this analysis it was thought most 
appropriate to include it under this category. In this assessment, the participant is given 
a piece of paper with 9 symbols corresponding to 9 digits; below it, are 4 rows of digits 
with empty spaces. The participant is asked to fill as many corresponding symbols as 
possible in 90 seconds192. The total number of correct digits completed was recorded 
and included in the study’s analyses. 
Executive function was also examined with Control Oral Word Association Test 
(COWAT)195-197. The COWAT is used for both language (verbal fluency) and executive 
function as a way to assess how a person communicates in daily life. It is important to 
note that some research has found age, sex and education effects with the COWAT 
(e.g., age-related declines, women slightly outperforming males and education beyond 
12-years favoring scores)197. In this assessment, the participant is asked to say as 
many words as they can about a given category in 60 seconds. The total number of 
words recalled is recorded. 
Attention and Working Memory. Attention and working memory was tested 
with the Backward Digit Span (BDS) and the Digit Span Forward Test (DSF)198,199. Both 
of these assessments date back to the 19th century when Wilhelm Wundt try to measure 
the scope of consciousness, now better known as working memory or retention200. The 
DSF is more indicative of short term auditory memory, while the BDS assesses more 
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the ability to manipulate verbal information while in temporary storage201. The digit span 
assesses working memory by asking the participant to recall digit sequences forward 
and backwards. The FDS is completed before the BDS. In the FDS the psychometrist 
tells the participant that he/she is going to say some numbers, to listen carefully and to 
repeat them back as soon as he/she is through. In the BDS, the participant hears the 
numbers and then is asked to repeat them backwards. Each correct response is worth 1 
point for a maximum total of 14 for each sub-score and a total score of 28. 
Language. Language was examined with the Boston Naming Test (30 item 
version)202,203. This is a classic confrontation naming test in psychology used to 
measure naming deficits204. Here, the participant is shown a series of 30 line-drawn 
pictures are presented to the participant (a maximum of 20 seconds are given per 
picture)204. If the participant has difficulty recalling the name of the picture, a stimulus 
cue is given. If the participant has difficulty recalling the name of the picture, a stimulus 
cue is given. If the participant incorrectly names the picture after a stimulus cue is given, 
a phonemic cue was provided. Several scores are estimated, including the total number 
of correct spontaneous responses, total number of correct responses following semantic 
cues, and total number of correct response following phonemic cues. 
Each cognitive domain was converted to z-scores for standardization and ease of 
interpretation. To assess overall cognitive performance, a composite cognitive score 
(CCS) was constructed by taking the average of the z-scores from each of the six 
cognitive domains.  
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Biological Measures 
Specimen collection of participants was performed at the University Hospital 
Motol in Prague, Czech Republic. Serum lipoprotein samples were collected in the 
morning after a 12-hour fasting period. Standard venipuncture methods were used. 
Specimens were stored and processed in-house within 1-3 hours after collection. 
Lipoproteins measured included in this study are: TC, LDL-C, TG and HDL-C. 
Continuous values of lipoproteins will be used in statistical models. Genotyping was 
performed by polymerase chain reaction (PCR) using oligonucleotide primers to identify 
the APOE gene polymorphism. The DNA from participants was obtained from blood 
leukocyte samples using standard technique205. For this analysis subjects with 
specimens collected ±60 days from the administration of the neuropsychological battery 
were included. 
 
Covariates 
Demographic variables were obtained at the time of cognitive testing and 
included sex, age (years), and maximum achieved education level. Age and education 
were analyzed as continuous variables. The Geriatric Depression Scale (GDS) was 
used as one of the covariates to assess depressive symptoms among participants, as it 
strongly correlates with cognitive performance206. This is a 30-item self-report 
assessment with scores 0-4 considered normal, 5-8 mild depression, 9-11 moderate 
and 12-15 severe depression. 
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Statistical analysis 
Statistical analysis was performed using SAS software, version 9.4 (Copyright © 
2002-2012 SAS Institute Inc. SAS and all other SAS Institute Inc. product or service 
names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA.). 
This study examined baseline characteristics overall and for men and women 
separately by independent samples t-test and Pearson chi-square test. Scores for 
cognitive tests were standardized to z-scores (mean=0 and one unit standard deviation) 
to enable comparison across the cognitive measurements scored on different scales. 
Higher z-scores reflect better cognitive performance.  APOE ε4 variable was coded to a 
dichotomous variable as ԑ4 carriers (ԑ2/ԑ4, ԑ3/ԑ4, or ԑ4/ԑ4) and non-carriers (ԑ2/ԑ2, 
ԑ2/ԑ3, ԑ3, ԑ3). Pearson correlation coefficients were obtained for all dependent and 
independent variables.  
For the first aim, ordinary least square regressions (OLS) were employed to 
examine the relationship between continuous lipoprotein levels of TC, LDL-C, TG and 
HDL-C and cognitive performance measured by the composite cognitive score while 
controlling for age, sex, education, and depressive symptoms (model 1). Adjustment for 
these covariates was done because they are known to be correlated with cognitive 
performance. Models were subsequently also adjusted for APOE ε4 allele (model 2).  
All models were applied to each of the six individual cognitive domains. To aid 
interpretation of the results including the magnitude of the observed associations, 
standardized regression coefficients are presented along with unstandardized 
regression coefficients. In addition standard error and effect sizes (adjusted R2) are 
provided for each of the models. 
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  For the second aim, a moderation effect by age, sex and/or APOE ԑ4 allele 
status between each lipoprotein (TC, LDL-C, TG and HDL-C) and cognitive function 
was examined by adding the interaction term of the lipoprotein and the potential 
moderator in the regression model. Continuous variables in the interaction were 
centered as recommended207. Interaction effects were estimated with each potential 
moderator (age, sex, APOE) for all significant associations between a lipoprotein and a 
cognitive outcome. Stratification by moderator values was used in cases when the 
interaction is statistically significant. However, stratification by sex was performed 
regardless of the moderation results in order to better compare the study results to 
previous studies. Some figures for the stratification of the significant moderation results 
were obtained using the ModGraph program207. 
A post hoc power analysis was conducted using G*Power statistical software208. 
The sample size of 112 was used for statistical power analysis and an 8 predictor 
variable equation (TC, LDL-C, TG, HDL-C, age, sex, education, GDS score) was used 
as a baseline. The recommended effect sizes used for this assessment were as follows: 
small (f2=.02), medium (f2=.15), and a large (f2=.35). The alpha levels used for the 
analysis was p<.05; critical F was 2.0295 and noncentrality parameter λ = 24.8863. 
Figure 3 shows that the post hoc analyses revealed the statistical power for this study 
was 0.95 for detecting an effect size of .22 medium effect, whereas the power exceeded 
.99 for the detection of a moderate to large effect size. Thus, there was more than 
adequate power (>0.80) at the moderate to large effect size level, but less than 
adequate statistical power at the small effect size level. The effect size obtain in this 
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study of 0.2 corresponds to a Cohen’s d= 0.4. Cohen’s d of 0.1-0.3 = small effect size, 
0.3-0.5 = intermediate effect and ≥ 0.5 large effect209.  
 
 
Results 
 
Descriptive Statistics 
Baseline characteristics of the sample stratified by sex are presented in Table 2. 
Overall, there were 6% more males than females included for analysis. The mean age 
was 73.2 years (SD 7.3); most were highly educated having some university education 
or above (79%, n=89). As expected for this cohort, males had higher levels of education 
than females (p=.006). The sample mean MMSE score was 27.6 (SD 2.0) and there 
were no significant differences in scores by sex (p=.840). The sample was borderline 
depressed with an average GDS score of 4.5 (scores of 0-4 are considered normal and 
5-8 mildly depressed). Depressive symptom scores were significantly higher in women 
than in men (p=.007). In general, older adults in the study had borderline TC, near or 
 
 
Figure 3. Linear Multiple Regression Plot of Power Analysis. 
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Table 2. Baseline Characteristics of the Participants. 
  Total 
Sample 
(N=112)  
100% 
Males 
(n=62)  
53% 
Females 
(n=50) 
47% 
p-value 
Mean Age (SD) 73.2 (7.3) 73.4 (7.4) 73.0 (7.2) .733 
Mean Education (SD) 14.4 (3.8) 15.3 (3.3) 13.2 (4.0) .003 
Education 
Secondary or below (< 11 years) 
Some University (12-15 years) 
Graduate Univ.+ (≥16 years) 
 
23 (20.5) 
44 (39.3) 
45 (40.2) 
 
9 (14.5) 
20 (32.3) 
33 (53.2) 
 
14 (28.0) 
24 (48.0) 
12 (24.0) 
 
.006 
Apolipoprotein ԑ4 allele (n=100) 
Present 
Absent 
 
26 (26%) 
74 (74%) 
 
15 (26.8) 
41 (73.2) 
 
11 (25.0) 
33 (75.0) 
 
.840 
Mean Lipoprotein Levels mmol/l (SD) 
Total Cholesterol* (n=95) 
LDL-C* (n=93) 
Triglycerides* (n=95) 
HDL-C* (n=96) 
 
5.41 (1.05) 
3.13 (0.95) 
1.42 (0.71) 
1.40 (0.43) 
 
5.09 (0.97) 
2.98 (0.89) 
1.42 (0.64) 
1.27 (0.37) 
 
5.78 (1.02) 
3.29 (1.00) 
1.41 (0.79) 
1.54 (0.44) 
 
.001 
.113 
.940 
.002 
Mean Geriatric Depression Scale (SD) 
(n=111) 
4.49 (3.45) 3.70 (3.15) 5.46 (3.59) .007 
Mean (SD) 
 
MMSE (n=112) 
Composite cognitive score†§(n=111) 
Verbal Memory 
AVLT 1-6 (n=111) 
AVLT 30 (n=110) 
Total Recall (n=109) 
Non-verbal (ROCFT-R) (n=80) 
Executive Function (n=111) 
COWAT (n=111 ) 
Digit Symbol (n=103) 
Visuospatial (ROCFT-C) (n=98) 
Language (BNT30) (n=101) 
Attention & Working Memory (n=110) 
BDS (n=110) 
FDS (n=110) 
 
27.6 (2.00) 
0.08 (0.43) 
0.20 (0.75) 
0.17 (0.90) 
0.14 (0.95) 
0.28 (0.71) 
0.05 (0.93) 
0.16 (0.75) 
0.23 (0.87) 
0.09 (0.90) 
0.09 (0.86) 
-0.24 (0.71) 
0.21 (0.81) 
0.21 (0.92) 
0.20 (0.89) 
 
27.6 (2.03) 
0.05 (0.47) 
0.12 (0.71) 
0.04 (0.11) 
0.03 (0.88) 
0.30 (0.70) 
0.07 (0.97) 
0.08 (0.74) 
0.14 (0.88) 
0.01 (0.92) 
0.06 (-0.15) 
-0.34 (0.66) 
0.24 (0.88) 
0.27 (0.97) 
0.20 (0.96) 
 
27.58 (1.98) 
0.13 (0.39) 
0.28 (0.81) 
0.33 (0.94) 
0.28 (1.03) 
0.25 (0.72) 
0.02 (0.90) 
0.26 (0.74) 
0.33 (0.85) 
0.18 (0.89) 
0.12 (-0.14) 
-0.12 (0.75) 
0.17 (0.71) 
0.14 (0.85) 
0.021 (0.81) 
 
.931 
.318 
.283 
.093 
.180 
.727 
.808 
.189 
.254 
.345 
.727 
.120 
.682 
.441 
.962 
 
Note. LDL-C = low-density lipoprotein; HDL-C = high-density lipoprotein; MMSE = Mini-Mental State Exam; AVLT 
1-6 = Auditory Verbal Learning Test trials 1-6; AVLT 30 = Auditory Verbal Learning Test 30 minute recall; 
ROCFT-R = Rey-Osterrieth Complex Figure Test – the Immediate Recall condition; COWAT = Control Oral Word 
Association Test; ROCFT-C = Rey-Osterrieth Complex Figure Test – the Copy condition; BDS = Backward Digit 
Span; FDS = Forward Digit Span;.*Optimal range: TC< 5.2mmol/l; LDL-C<3.4mmol/l; Triglycerides<1.7mmol/l; 
HDL-C ≥1.5mmol/l † z-scores §Composite cognitive score=mean of the sum of cognitive domains. 
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above optimal LDL-C, and normal levels of TG and HDL-C. Significant sex differences 
were observed for TC and HDL-C lipoproteins.  Females had higher levels of TC 
(p=.001) and HDL-C (p=.002) than males, but no differences were observed for LDL-C 
(p=.113) or TG (p=.940). Table 2 also shows there were no significant sex differences in 
scores for the composite cognitive score or when assessing any of the specific cognitive 
domains. When composite cognitive scores were further examined, there were no 
statistically significant differences by sex (p=.318), age (p=.360), education (p=.393), or 
depressive symptoms score (p=.396).  
Eighty nine percent of the older adults had information on their APOE. Two thirds 
were APOE ε4 allele non-carriers and this did not differ by sex (p=.840). In table 3 
baseline characteristics are presented stratified by APOE ε4 allele group (carriers vs. 
non-carriers). In general non-carriers of the APOE ε4 allele scored higher in the MMSE 
(p=.047) and verbal memory (p<.001). Non-carriers also had a borderline significant 
advantage in non-verbal memory (p=.050) over the carriers. Furthermore, despite the 
lack of statistical significance, in the CCS and verbal memory tests, carriers of the 
APOE ε4 allele scored considerably lower than non-carriers of the gene.  
Figure 4 shows the distribution of the lipids and the 95% Confidence Intervals 
(CI) for non-carriers and carriers of the APOE ε4 allele. No statistical significant 
differences were observed for any of the lipoprotein levels between carriers and non-
carriers of the ε4 allele. However, carriers of the APOE ε4 allele had much higher levels 
of LDL-C and TG than non-carriers. 
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Correlations 
In table 4, the Pearson correlation coefficients among demographic variables and 
lipoproteins are presented. Overall, it was observed that older ages yielded lower levels 
of TC, LDL and TG and higher levels of HDL-C, but none of these correlations were 
statistically significant (p’s>.05). Female sex correlated with lower levels of education 
(p=.003) and higher levels of TC (p=.001) and HDL-C (p=.002).  Higher MMSE scores 
correlated with higher levels of education (p=.023) and being non-carriers of the APOE 
ε4 allele (p=.047). TC was positively correlated with LDL-C (p<.001) and TG (p=.009) 
Table 3. Baseline Characteristics of Participants by APOE ε4 Allele group. 
 
 
APOE ε4 allele 
positive  
(n= 26) 
APOE ε4 allele 
negative 
(n= 74 ) p-value 
                                                        Mean (SD) 
Age  71.7 (6.4) 73.9 (7.4) .184 
Sex 
Males 
Females 
 
15 (57.7) 
11 (42.3) 
 
41 (55.4) 
33 (44.6) 
 
 
.840 
Education 13.3 (4.3) 14.6 (3.5) .135 
    
Total cholesterol (TC)* 5.5 (0.8) 5.4 (1.0) .695 
Low-density lipoprotein cholesterol (LDL-
C)* 
3.4 (0.8) 3.0 (0.9) .067 
Triglycerides (TG)* 1.6 (0.8) 1.3 (0.6) .059 
High-density lipoprotein cholesterol (HDL-
C)* 
1.3 (0.4) 1.4 (0.4) .085 
    
Geriatric Depression Scale 3.6 (2.9) 4.2 (3.2) .424 
Mini Mental State Exam 27.0 (2.1) 27.9 (1.9) .047 
    
Composite cognitive score*** -0.005(0.37) 0.17 (0.43) .072  
Verbal Memory -0.23 (0.77) 0.41 (0.68) <.001 
Non-verbal Memory -0.29 (0.96) 0.19 (0.90) .050 
Visuospatial 0.14 (0.74) 0.20 (0.77) .750 
Executive Function 0.14 (0.71) 0.23 (0.76) .595 
Language -0.02(-0.34) -0.33 (-0.50) .067 
Attention & Working Memory 0.23 (0.73) 0.25 (0.87) .943 
 
Note. *Optimal range: TC< 5.2mmol/l; LDL-C<3.4mmol/l; Triglycerides<1.7mmol/l; HDL-C ≥1.5mmol/l ** z-scores 
***Composite cognitive score=mean of the sum of cognitive domains. 
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and negatively with HDL-C (p=.005). Higher levels of LDL-C correlated with higher 
levels of TG (p=.002) and HDL-C correlated negatively with TGs (p<.001). 
 
 
 
 
 
Figure 4. Distribution of the Lipoproteins by APOE ε4 allele. 
Note.  *Optimal Range: Total Cholesterol (TC) < 5.2mmol/l; Low-density lipoprotein cholesterol (LDL-C) < 3.4mmol/l; 
Triglycerides (TG) < 1.7mmol/l; High-density lipoprotein cholesterol (HDL-C) > 1.5 mmol/l. Solid blue lines represent 
the normal distribution and the dashed red lines represent the Kernel density, or non-parametric. APOE4=0 for non-
carriers of the APOE ε4 allele and APOE4=1 for carriers of the APOE ε4 allele. 
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Sex differences in the correlations within the lipoproteins and APOE ε4 allele is 
presented in table 5. A positive linear relationship was observed in both sexes between 
TC and LDL-C, both p’s<.001 and between LDL-C and TGs (males (p=.041) and 
females (p=.016)). A negative correlation was found in both sexes between TG and 
HDL-C, meaning that low levels of HDL-C are correlated with high TG levels; however, 
78% of the variation in females (r2=.22) and 85% in males (r2=.15) cannot yet be 
explained. In females, APOE ε4 allele correlated with higher levels of TG (p=.018) and 
lower levels of HDL-C (p=.047). 
Table 4. Pearson Correlation Coefficients for Demographic Variables and 
Lipoproteins. 
 1 2 3 4 5 6 7 8 9 
1. Age 
(n=112) 
1         
2. Sex 
(n=112) 
-0.03 1        
3.   Education 
(n=112) 
0.14 -0.28** 1       
4.   GDS 
      (n=111) 
-0.06 0.25** -0.19* 1      
5.   MMSE  
(n=112) 
-0.10 -0.01 0.21* -0.12 1     
6.   APOE ε4 
allele 
(n=100) 
-0.13 -0.02 -0.15 -0.08 -0.20* 1    
7.   TC 
(n=95) 
-0.05 0.33** -0.19 0.08 -0.001 0.04 1   
8. LDL-C  
(n=93) 
-0.04 0.16 -0.13 0.004 -0.04 0.20 0.86*** 1  
9. TG  
(n=95) 
-0.10 -0.01 -0.29** 0.03 -0.01 0.20 0.27** 0.33** 1 
10. HDL-C 
(n=96) 
0.06 0.31** 0.04 0.09 0.04 -0.18 0.29** -0.05 -0.42*** 
 
Note. P-values: *p<.05, **p<.01, ***p<.001. GDS=Geriatric Depression Scale, MMSE=Mini Mental State Exam, 
TC=total cholesterol, LDL-C=low-density lipoprotein cholesterol, TG= triglycerides, HDL-C=High-density 
lipoprotein cholesterol. 
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Table 6 presents the correlations for each of the cognitive function tests 
performed and lipoproteins. Higher CCS correlated with lower TG (p=.015) and higher 
HDL-C (p=.006) and these significant relationships were only statistically significant 
among women. Visuospatial skills correlated positively with HDL-C for the whole sample 
(p=.033). Overall, lower TG in women was significantly correlated with better verbal 
(p=.043) and non-verbal memory (p=.042) and visuospatial function (p=.010), but not in 
men.  Additionally, only in women, higher levels of HDL-C correlated with better 
attention and working memory (p=.037). Being a carrier of the APOE ε4 allele had a 
linear relationship with lower verbal memory (p<.001) and borderline with non-verbal 
memory (p=.050). In women, carriers of the APOE ε4 allele showed linear relationships 
with lower scores in CCS (p=.003), verbal (p<.001) and non-verbal memory (p=.008). 
Table 5. Pearson Correlation Coefficients among Lipoproteins and APOE ε4 Allele 
Stratified by Sex. 
 
 1 2 3 4 
1. TC 
Males 
Females 1    
2. LDL-C 
Males 
Females 
0.83*** 
0.88*** 1   
3. TG 
Males 
Females 
0.26   
0.33* 
0.30* 
0.36* 1  
4. HDL-C 
Males 
Females 
0.29* 
0.11 
-0.005 
-0.20 
-0.39** 
-0.47** 1 
5. APOE ε4 allele 
Males 
Females 
0.11 
0.005 
0.26 
0.14 
0.04 
0.36* 
-0.05 
-0.31* 
 
Note. *p<.05, **p<.01, ***p<.001. TC=Total Cholesterol, LDL-C=Low Density Lipoprotein cholesterol, 
TG=triglycerides, HDL-C=High Density Lipoprotein cholesterol. 
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 Table 7 presents the Pearson Correlation Coefficients between demographics 
and cognitive domains among men and women. These correlations were done to 
determine if the linear associations seen particularly among women in each of the 
cognitive domains correlated with age, education or MMSE score.  
With the exception of visuospatial and attention and working memory in women, 
all cognitive function tests showed a significant moderate linear relationship with MMSE 
for both men and women. Although age showed a negative correlation with CCS, verbal 
memory and executive function, these relationships were not statistically significant; 
however, among males age was negatively correlated with non-verbal abilities (p=.025). 
Among females, education positively correlated with verbal (p=.003) and non-verbal 
memory (p=.002). 
Table 6. Pearson Correlation Coefficients between Lipoproteins and Cognitive Domains. 
 
 CCS Verbal 
Memory 
Non-
verbal 
Visuo-
spatial 
Executive 
Function 
Language Attention 
& Working 
Memory 
TC 
Males 
Females 
0.15 
0.14 
0.13 
0.02 
-0.07 
0.08 
-0.01 
0.08 
-0.02 
0.09 
0.16 
0.01 
0.12 
0.02 
0.14 
0.15 
0.21 
-0.02 
0.05 
0.07 
0.09 
LDL-C 
Males 
Females 
0.03 
0.03 
0.01 
-0.003 
-0.05 
0.02 
-0.07 
-0.09 
-0.001 
0.01 
0.07 
-0.04 
0.02 
-0.05 
0.06 
0.07 
0.14 
-0.04 
-0.02 
0.01 
-0.04 
TG 
Males 
Females 
-0.25* 
-0.11 
-0.42** 
-0.16 
0.01 
-0.30* 
-0.23 
-0.12 
-0.36* 
-0.21 
0.04 
-0.40** 
-0.06 
0.06 
-0.18 
-0.03 
-0.23 
0.14 
-0.11 
-0.10 
-0.13 
HDL-C 
Males 
Females 
0.28** 
0.19 
0.38** 
0.15 
0.08 
0.17 
0.13 
0.17 
0.18 
0.23* 
0.20 
0.26 
0.14 
0.004 
0.21 
0.10 
0.18 
-0.06 
0.19 
0.16 
0.32* 
APOE ε4 allele 
Males 
Females 
-0.18 
-0.02 
-0.43** 
-0.37*** 
-0.17 
-0.60*** 
-0.23 
-0.06 
-0.47** 
-0.03 
0.04 
-0.12 
-0.05 
0.03 
-0.16 
0.19 
0.14 
0.25 
-0.01 
0.62 
-0.13 
 
Note. *p<.05, **p<.01, ***p<.001. TC=Total Cholesterol, LDL-C=Low Density Lipoprotein cholesterol, 
TG=triglycerides, HDL-C=High Density Lipoprotein cholesterol. 
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Ordinary Least Square Regression Results 
An ordinary least square (OLS) regression analysis was conducted to test the 
hypothesis for the first aim which stated high levels of TC, LDL-C and HDL-C and low 
levels of TG are associated with better cognitive function (higher composite cognitive 
scores and higher scores in each individual cognitive domain: nonverbal and verbal 
memory; visuospatial function; executive function; attention and working memory; and 
language). Associations between lipoproteins and each cognitive domain are shown in 
Table 8. In model 1 better CCS was associated with lower levels of TG (p=.036) and 
higher levels of HDL-C (p=.008).  When examining specific cognitive domains, 
participants with higher levels of HDL-C performed better in visuospatial function 
(p=.028) and attention/working memory (p=.037). In model 2, when additional 
adjustment was performed for APOE ε4 allele, significance between high levels of HDL-
 
Table 7. Pearson Correlation Coefficients between Demographics and Cognitive 
Domains by Sex. 
 CCS Verbal 
Memory 
Non-
verbal 
Visuo-
spatial 
Executive 
Function 
Language Attention & 
Working 
Memory 
AGE 
Males 
Females 
-0.02 
-0.04 
-0.15 
-0.14 
-0.34* 
-0.02 
0.03 
0.04 
-0.04 
-0.04 
0.02 
0.12 
0.14 
-0.02 
EDUCATION 
Males 
Females 
0.06 
0.21 
-0.01 
0.41** 
-0.04 
0.48** 
0.03 
-0.001 
-0.01 
0.01 
0.007 
-0.40** 
0.15 
0.002 
MMSE 
Males 
Females 
0.64*** 
0.53*** 
 
0.56*** 
0.66*** 
0.58*** 
0.67*** 
0.46*** 
0.29 
0.47*** 
0.36** 
-0.34* 
-0.45** 
0.45*** 
0.05 
 
Note. *p<.05, **p<.01, ***p<.001. CCS= Composite cognitive Score; MMSE=Mini-Mental State Exam. 
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Table 8. Ordinary Least Square Regressions Modeling the Association between 
each Lipoprotein and Cognitive Function. 
 
 Model 1  Model 2 
 b SE β p AdjR2 n  b SE β p AdjR2 n 
Composite 
cognitive 
score* 
             
TC 0.06 0.046 0.154 .158 .03 94  0.08 0.048 0.180 .102 .07 88 
LDL-C 0.01 0.049 0.282 .790 .01 92  0.01 0.049 0.028 .790 .01 92 
TG -0.13 0.064 -0.224 .036 .07 94  -0.11 0.068 -0.174 .115 .09 89 
HDL-C 0.29 0.108 0.283 .008 .10 95  0.26 0.109 0.262 .018 .11 89 
Verbal 
Memory 
             
TC 0.02 0.080 0.024 .821 .03 94  -0.005 0.078 -0.007 .947 .20 88 
LDL-C 0.004 0.084 0.005 .962 .03 92  0.02 0.084 0.026 .796 .21 86 
TG -0.12 0.115 -0.107 .312 .08 94  -0.03 0.114 -0.023 .814 .25 89 
HDL-C 0.19 0.196 0.105 .327 .07 95  0.09 0.181 0.052 .607 .23 89 
Non-Verbal 
Memory 
             
TC 0.03 0.114 0.035 .779 .09 68  0.01 0.127 0.013 .918 .14 64 
LDL-C -0.02 0.121 -0.029 .853 .07 66  -0.04 0.135 -0.040 .752 .13 62 
TG -0.27 0.156 -0.214 .083 .19 67  -0.15 0.177 -0.114 .383 .20 64 
HDL-C 0.34 0.276 0.150 .226 .12 69  0.27 0.28 0.123 .335 .16 65 
Visuospatial              
TC 0.07 0.097 0.089 .444 .01 84  0.10 0.103 0.119 .327 -.02 78 
LDL-C 0.002 0.101 0.003 .981 .01 81  0.02 0.109 0.023 .850 -.04 75 
TG -0.23 0.125 -0.213 .069 .06 83  -0.15 0.132 -0.145 .258 -.01 78 
HDL-C 0.47 0.211 0.250 .028 .07 84  0.42 0.204 0.247 .043 .03 78 
Executive 
Function  
             
TC 0.05 0.079 0.069 .526 .02 94  0.11 0.086 0.144 .200 .02 88 
LDL-C -0.002 0.087 -0.003 .980 -.005 92  0.07 0.098 0.083 .459 -.003 86 
TG -0.08 0.115 -0.073 .508 -.009 94  -0.02 0.128 -0.021 .854 -.01 89 
HDL-C 0.24 0.196 0.133 .228 .01 95  0.19 0.203 0.108 .355 -.003 89 
Language              
TC 0.06 0.085 0.085 .483 .04 86  0.08 0.094 0.104 .365 .06 80 
LDL-C 0.005 0.083 0.007 .951 .06 84  -0.01 0.089 -0.011 .918 .15 78 
TG -0.11 0.114 -0.107 .346 .06 86  -0.23 0.123 -0.216 .070 .11 81 
HDL-C 0.11 0.182 0.066 .555 .05 87  0.19 0.178 0.118 .298 .12 81 
Attention & 
Working 
Memory 
             
TC 0.07 0.091 0.092 .420 -.03 93  0.08 0.101 0.092 .434 -.05 87 
LDL-C -0.01 0.098 -0.008 .943 -.05 91  -0.01 0.112 -0.013 .910 -.06 85 
TG -0.01 0.132 -0.094 .400 -.03 93  -0.11 0.148 -0.087 .463 -.05 88 
HDL-C 0.46 0.217 0.233 .037 .01 94  0.46 0.226 0.237 .044 -.003 88 
 
Note. * TC=Total Cholesterol, LDL-C=Low Density Lipoprotein cholesterol, TG=triglycerides, HDL-C=High Density Lipoprotein 
cholesterol. Composite cognitive score=mean of the sum of cognitive domains. β= standardized regression coefficient. Results 
in model 1 were adjusted for age, sex, education, and depressive symptoms. Results in model 2 were additionally adjusted for 
APOE4. 
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C, and cognitive measures (i.e., CCS (p=.018), visuospatial function (p=.043) and 
attention and working memory (p=0.44)) remained. 
 
Moderation Analysis Results 
To test the hypothesis that age, sex and/or APOE ԑ4 allele moderate the 
relationship between the lipoproteins and the cognitive tests (Aim 2) a moderation 
analysis was performed by inserting an interaction term in the equation for all significant 
cognitive associations. Unstandardized betas were used to calculate the figures, but 
standardized betas are reported in the text to ease the interpretation of the results. 
Moderations on the Association of TG and HDL-C on CCS.  Multiple 
regression models were tested to investigate whether the association between TG and 
the CCS and between HDL-C and CCS was moderated by age, sex, or APOE ԑ4 allele. 
As illustrated in figure 5, APOE ԑ4 allele did modify the association between TG and the 
CCS (b=0.27, SEb=0.134, β=0.28; p=.044) and between HDL-C and the CCS (b=-0.56, 
SEb=0.236, β=-0.28; p=.020).  However, the age-by-TG interaction term was not 
significant (b=0.001, SEb=0.008, β=0.01; p=.910), nor was the age- by-HDL- C (b=-
0.009, SEb=0.015, β=-0.07; p=.526). Sex also had no moderation effect on the 
relationship between TG and CCS (b=-0.11, SEb=0.123, β=-0.31; p=.356) or between 
HDL-C and CCS (b=0.034, SEb=0.217, β=0.05; p=.875).   
Moderation on the Association of HDL-C on Visuospatial Function. To 
investigate whether the association between HDL-C and visuospatial function was 
moderated by age, sex, or APOE ԑ4 allele, an interaction term with these variables was 
added separately to the first multiple regression model. Results indicated that neither 
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the age-by-HDL-C interaction term (b=-0.0006, SEb=0.03, β=-0.002; p=.984), the  sex-
by-HDL-C interaction term (b=0.02, SEb=0.426, β=0.02; p=.953), nor the APOE ԑ4 
allele-by-HDL-C interaction term (b=-0.52, SEb=0.449, β=-0.16; p=.247) were significant 
on visuospatial function.  
 
 
Moderation on the Association of HDL-C on Attention and Working 
Memory. To examine whether the association between HDL-C and attention and 
working memory was moderated by age, sex, or APOE ԑ4 allele, the model 1 of the 
multiple regression models were applied adding separate interaction terms (e.g. 
age*HDL-C, sex*HDL-C, APOE ԑ4 allele*HDL-C). Results indicated that none of the 
 
Figure 5. Standardized Regression Coefficients for the Moderation of APOE ε4 on 
the Relationship between: TG and CCS and HDL-C and CCS, Controlling for Age, 
Sex, Education and Depressive Symptoms. 
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interactions were significant: age-by-HDL-C interaction term on attention and working 
memory was (b=-0.03, SEb=0.030, β=-0.13; p=.250), the sex-by-HDL-C (b=0.12, 
SEb=0.433, β=0.10; p=.783) and the APOE ԑ4-by-HDL-C interaction term was (b=-0.59, 
SEb=0.500, β=-0.16; p=.237). 
Sex-Stratified Results. Despite the fact that no interaction was detected by sex, 
sex-stratification was performed on those cognitive tests that had statistically significant 
results in the first regression model in order to match this study with recent previous 
research on lipoproteins and cognition 45,85 in which separate results for men and 
women were presented. Table 9 shows the significant findings of the exploratory sex-
stratified analysis conducted, in which significant results were only seen among women. 
Lower levels of TG were associated with better CCS in women (p=.013), but not in men 
(p=.550). Additionally higher levels of HDL-C were also associated with better CCS in 
women only (p=.019), not men (p=.118). For the significant individual cognitive domains 
reported in model 1, lower levels of TG were also linked with better visuospatial function 
in women only (p=.006), not men (p=.799) and higher levels of HDL-C were related to 
better attention and working memory among women (p=.039), not men (p=.297). 
The lack of interaction of sex by lipoproteins is important put into the context of 
the sex-stratified results presented in the ordinary least square regression models. It 
appears that while the associations were stronger for women, they were also present for 
men, just not at the same magnitude, hence deeming the sex-by-lipoprotein interactions 
non-significant.  
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 Stratification by APOE ε4 Allele. Stratification by carriers vs. non-carriers of the 
APOE ε4 allele was also performed for the association between TG and CCS and 
between HDL-C and the CCS as these were the only statistically significant results in 
the moderation analysis. Table 10 presents the results for the stratification by carriers 
vs. non-carriers of the APOE ε4 allele. The significant associations between the 
lipoproteins and the cognitive domains predominated only among non-carriers of the 
APOE ε4 allele. Lower levels of TG and higher levels of HDL-C are only associated with 
cognitive function among non-carriers of the APOE ε4 allele. Figures 6 and 7 show the 
interaction of APOE ε4 allele and the stratification results by carriers or non-carriers of 
 
Table 9. Ordinary Least Square Regressions Modeling the Association between each 
Lipoprotein and Cognitive Function among Men and Women Adjusting for Age, 
Education, and Depressive Symptoms. 
 
 Males 
(n=62) 
 Females 
(n=50) 
 b SE β p Adj 
R2 
n b SE β p Adj 
R2 
n 
Composite cognitive score*          
TC 0.097 0.075 0.193 .204 .01 50 0.044 0.058 0.115 .458 .02 44 
LDL-C 0.018 0.084 0.033 .834 -.02 48 0.002 0.060 0.007 .966 .01 44 
TG -0.065 0.109 -0.089 .550 -.08 49 -0.195 0.075 -0.403 .013 .15 45 
HDL-C 0.299 0.188 0.226 .118 .05 50 0.300 0.123 0.349 .019 .14 45 
Visuospatial             
TC 0.209 0.146 0.232 .161 .03 43 -0.029 0.143 -0.034 .837 -.04 41 
LDL-C 0.078 0.158 0.084 .625 -.02 41 -0.071 0.147 -0.081 .631 -.03 40 
TG 0.045 0.177 0.041 .799 -.01 42 -0.531 0.182 -0.499 .006 .16 41 
HDL-C 0.485 0.312 0.242 .128 .04 43 0.484 0.304 0.250 .120 .04 41 
Attention & Working Memory          
TC 0.145 0.146 0.152 .324 -.02 50 0.088 0.123 0.118 .480 -.08 43 
LDL-C 0.052 0.165 0.050 .752 -.07 48 -0.013 0.126 -0.018 .917 -.09 43 
TG -0.113 0.218 -0.078 .607 -.05 49 -0.152 0.165 -0.163 .363 -.08 44 
HDL-C 0.389 0.369 0.157 .297 -.04 50 0.545 0.255 0.330 .039 .02 44 
 
Note. *Composite cognitive score=mean of the sum of cognitive domains. Stand β= standardized regression coefficient. 
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the ε4 allele. Low TG yielded higher CCS (p=.022) on non-carriers of the APOE ε4 
allele, but not on carriers (p=.470). Furthermore, figures 8 and 9 show the APOE ε4 
allele moderation, non-carriers of the APOE ε4 allele with high HDL-C levels also 
obtained higher CCS (p=.003), but not APOE ε4 allele carriers (p=.289). Additionally, it 
is interesting to note that in each of the significant findings the levels of lipoproteins 
were in opposite directions among carriers vs. non-carriers. 
 
 
 
 
 
Table 10. Ordinary Least Square Regressions Modeling the Association between 
each Lipoprotein and Cognitive Function among Carriers vs. Non-Carriers of the 
APOE ε4 Allele Adjusting for Age, Sex, Education, and Depressive Symptoms. 
 
 APOE ε4 carriers 
(n=26) 
 APOE ε4 non-carriers  
(n=74) 
 b SE β p AdjR2 n  b SE β p AdjR2 n 
Composite 
cognitive score* 
             
TG 0.085 0.115 0.190 .470 -.14 25  -0.206 0.087 -0.288 .022 .12 64 
HDL-C -0.222 0.203 -0.249 .289 -.10 25  0.401 0.130 0.388 .003 .17 64 
 
Note. *Composite cognitive score=mean of the sum of cognitive domains. B= non-standardized regression 
coefficient. Stand β= standardized regression coefficient. 
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Figure 6.  Moderation of the Effect of TG on CCS by Carriers or Non-Carriers of 
the APOE ε4 Allele. 
Note. TG = triglycerides, APOE = APOE ε4 allele. 
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Figure 7. Moderation of the Effect of TG on CCS by APOE ε4 Allele. 
Note. TG = triglycerides, APOE = APOE ε4 allele. 
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Figure 8. Moderation of the Effect of HDL-C on CCS by Carriers or Non-Carriers of 
the APOE ε4 allele. 
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Figure 9. Moderation of the Effect of HDL-C on CCS by APOE ε4 Allele. 
Note. HDL-C = High-density lipoprotein cholesterol, APOE = APOE ε4 allele. 
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Discussion 
Using a volunteer sample of older adults tested at a memory clinic in Prague, 
Czech Republic, this study addressed the first aim assessing the association of total 
cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and 
high-density lipoprotein cholesterol (HDL-C) in relation to overall cognitive performance 
measured through a composite cognitive score as well as individual scores on six well-
established cognitive domains (verbal memory, non-verbal memory, visuospatial, 
executive function, attention/working memory, and language). Results obtained indicate 
an association between lower TG and higher levels of HDL-C with better overall 
cognitive performance after adjustment for age, sex, education, and depressive 
symptoms with only high HDL-C results remaining significant after additionally 
adjustment for APOE ε4 allele. Results also show that high levels of HDL-C were 
associated with better visuospatial function and attention and working memory. 
However, this study was not able to detect any association between other lipoproteins 
and cognitive performance measures. Furthermore, when addressing the second aim of 
this study, results indicated that only APOE ε4 allele had a moderating effect on the 
association between low TG and better CCS and between high HDL-C and better CCS.  
 
Specific Discussion of the Regression Findings 
Triglycerides and CCS. Few studies in the literature have looked at TG and 
cognitive function46,85,138,210,211, but overall these studies seem to show a non-linear 
association, whereby very low or very high TGs are associated with cognitive function. 
The relationship found in this study between low TG and better cognitive function 
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measure as a composite cognitive score is supported by several studies. An earlier 
cross-sectional study by Kilander and colleagues (1997) studied men 69-74 years of 
age from Uppsala, Sweden and found a similar association between high plasma TG 
and poor cognitive performance210. Another earlier study in diabetics found that higher 
TG levels were associated with decrease cognitive performance measure by the digit 
substitution test, digit span backwards and a measure of reaction time211. More recent 
findings from a 16-year longitudinal study of health and cognition found an association 
between high TG and worse cognitive performance only among men before the age of 
65 before controlling for variables of interest, but not among women85. However, some 
have found contrasting findings.  
A recent analysis of 836 participants from the Chinese Longitudinal Healthy 
Longevity Survey observed that high normal TG levels were associated with better 
preserved cognitive function (measured with the MMSE) after adjusting the models for 
covariates138. These inconsistent findings between the studies are not surprising.  
Differences in methodologies, samples, and statistical analyses may partially explain 
differences in the results. A recently completed clinical trial in the United Kingdom 
looking at the effects of TG on age-related cognitive function decline in older adults may 
be able to provide further understanding of this association in the near future 
(https://clinicaltrials.gov/show/NCT01702480). This cross-over assignment study looked 
at 14-day treatment periods investigating cognitive performance and tolerability 
(gastrointestinal side effects) of the drug GSK2981710, expected to lower medium-
chain TG in adults between 55 and 80 years of age. This gold-standard type of study 
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may bring further insight into the association between TG and cognitive performance in 
older adults. 
HDL-C and CCS. Since the 1980’s HDL-C has been known to be a protective 
factor for atherosclerosis and cardiovascular disease212. But only more recently have 
higher levels of HLD-C been associated with better cognitive performance, especially 
among older adults49,85,127,137,213. Results from this study agree with these previous 
findings, higher levels of HDL-C were found associated with better cognitive 
performance. Moreover, the association between higher HDL-C levels and better overall 
cognitive performance was maintained after additional adjustment for APOE ε4 allele, 
which is consistent with previous research findings45,48,85,165. 
Low levels of HDL-C have been found associated with low gray matter volume in 
cognitively normal adults214 and grey matter is also present in the spinal cord. Studies 
have found that among all the circulating serum lipoproteins, HDL-C is the only one 
found in cerebrospinal fluid215,216. HDL-C is known to help maintain the homeostasis of 
intracellular cholesterol and is involved in reverse cholesterol transport of other lipids 
from the tissues, including the brain to the liver, which may explain why people with low 
HDL-C levels are displaying lower cognitive function than those with higher HDL-C 
levels. Perhaps the lack of a more efficient reverse cholesterol transport system 
compromises brain homeostasis and prompts for an accumulation of toxic brain 
byproducts such as amyloid-β yielding lower cognitive performance. 
HDL-C and Visuospatial Function. Results from this study indicated high levels 
of HDL-C were related to better visuospatial function, even adjusting for APOE ε4 allele. 
Although not many studies have addressed this association in the literature, a previous 
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study from the third National Health and Nutrition Examination Survey, 1988-1994, was 
not able to find a statistically significant association between visuomotor speed and 
HDL-C , the only association found was in men with low serum TC and non-HDL 
cholesterol (TC minus HDL-C)217. Future research should be inclusive of visuospatial 
function to supplement these findings.  
HDL-C and Attention and Working Memory. In this study high levels of HDL-C 
yielded better attention and working memory performance. This result is in agreement 
with some studies reported in the literature. An analysis from the Whitehall II Study also 
showed high levels of HDL-C associated with better attention and working memory213. 
Károssy and colleagues (2007) also found that the highest levels of HDL-C yielded 
better working memory performance in postmenopausal women using the digit span 
backwards. These authors suggested that HDL-C might perhaps be protecting frontal 
lobe functions on which working memory is dependent165. Future studies looking at the 
association between HDL-C and working memory could benefit of functional magnetic 
resonance imaging (fmRI) protocols to further understand the physiological aspects of 
this association. 
 
Specific Discussion on Moderation 
Few studies have been performed looking at the interaction between age, sex 
and APOE ε4 allele on the relationship between lipids and cognitive function. In this 
study, moderation was performed on all significant findings from the first regression 
model. However, no moderation effect was found between age or sex and any of the 
lipoproteins and the CCS. In addition, none of the moderators were found to have an 
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effect on the association between TG and HDL on any of the individual cognitive 
domains that were statistically significant in model 1. Several possible explanations for 
this may be posed. First, the nature of the neuropsychological test may have influenced 
the moderation, as most of these tests have been shown to have age and/or sex 
effects. Second, sex moderation analysis was underpowered due to the low number of 
participants in the stratified sex groups. In addition, only 26 individuals in this study were 
carriers of the APOE ε4 allele, therefore interactions with the individual cognitive test 
may have also been difficult to detect. Overall, these findings suggest that further 
moderation analysis with cognitive tests may be needed; as it is likely that cognitive 
tests currently used may also have APOE ε4 allele effects. 
Moderation of APOE ε4 Allele in the Association between TG and Cognitive 
Performance. APOE ε4 allele was found to moderate the association between low TG 
and better CCS in this study. This suggests that having at least one APOE ε4 allele 
strengthens the association between high TGs and lower cognitive performance in older 
adults. Unfortunately to the author’s knowledge only one study has looked at APOE ε4 
allele moderation in the association of TG and cognitive performance46. In a sample of 
participants over the age of 65 from the Betula project, de Frias and colleagues were 
not able to find any significant interactions between APOE4 and TG for any of the 
cognitive domains they tested. Further stratification of the association between TG and 
CCS among carriers and non-carriers of the APOE ε4 allele in this study showed a 
significant association between high TG and lower CCS in non-carriers only46. 
Understanding the moderation effect of not only APOE ε4 allele, but age and sex as 
well on the cognitive function of a cognitively normal older adult population, may provide 
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insight into the need to develop different preventive interventions to address the needs 
of diverse genetic populations218.  
Moderation of APOE ε4 Allele in the Association between HDL-C and 
Cognitive Performance. This study found that only APOE ε4 allele moderated the 
association between high HDL-C and better CCS. Moderation analysis for age and sex 
did not yield any significant results. A study by Atzmon and colleagues (2012) was also 
not able to see any interaction between HDL-C and sex45. When the sample was 
stratified by APOE ε4 allele carriers versus APOE ε4 allele non-carriers, high levels of 
HDL-C were associated with higher composite cognitive scores in non-carriers of the 
APOE ε4 allele only, suggesting that the differences between HDL-C-cognition 
associations were larger for APOE4 carriers. This is consistent with previous findings172. 
In a study of 1,395 adults over the age of 65 participating in the “Tone Project” in Japan, 
investigators divided the group into carriers (n=277) and non-carriers (n=1,118) of the 
APOE ε4 allele and tested cognitive function with a CCS and individually in attention, 
memory, language ability, and reasoning. They found that among non-carriers of the 
APOE ε4 allele high levels of HDL-C yielded higher scores in all the domains tested, but 
not among carriers of the gene172. This finding is very important as HDL-C may be 
targeted to prevent the loss of cognitive function on non-carriers of the APOE ε4 allele.  
Sex-Stratified Results. Furthermore, in the current study sex-stratified results 
indicate a female predominated association between low TG, high HDL-C and better 
cognitive performance. In addition, the link between high HDL-C and better attention 
and working memory also prevailed among women only. Overall, the associations 
observed for HDL-C and cognition were more slightly pronounced for women, which is 
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in agreement with previous research85,127,219. Though it is important to note, no sex-by-
HDL-C interactions were statistically significant. Still, one possible explanation for the 
stronger associations among women may be that a greater range of HDL-C levels tends 
to be observed in women compared to men. Though a relationship was observed 
between lower TG levels and better visuospatial skills only among women, which is in 
accordance with Reynolds et al. (2010) who found that lower TG levels were predictive 
of spatial ability, the contrast between the strength of the associations for men vs. 
women was not great enough to allow for a statistical significant interaction of sex-by-
TG in relation to cognition. It can be speculated that the relationship between low TG 
and better CCS and visuospatial function among women may be somewhat influenced 
by the level of education achieved given that lower TG showed a linear relationship with 
higher education. However, this can be questioned since women in this sample had 
statistically significant lower education level than the males. Further studies are needed 
to confirm/refute these findings. 
 
Limitations 
Despite the inclusion of all commonly used measures of blood lipids in the 
analyses, only TG and HDL-C showed consistent association with cognition. 
Theoretically, it is not completely surprising that HDL-C was the main lipoprotein driving 
the association with cognitive performance given that only the relatively small HDL-C 
particles are known to actively pass the brain barrier, prevent the formation of amyloid-β 
in the brain216 and have anti-inflammatory properties220,221. Additionally, this study did 
not take into consideration any genetic disorders affecting lipoproteins such as familial 
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hypoalphalipoproteinemia in which levels of HDL-C are extremely low69,222 or familial 
hypertriglyceridemia223 in which very high levels of TG remain constant. Perhaps, to 
better capture the combined effects of these blood lipids on cognitive function, 
longitudinal analysis with multiple consistent lipoproteins and cognitive measures are 
needed from mid adulthood into older ages. The lack of association between other 
measures of blood lipids and cognition has also been observed in other cross-sectional 
studies49,129. 
Some additional limitations should be mentioned. Due to the cross-sectional 
nature of this study, it is not possible to indicate whether lipoprotein levels relate to 
change in cognitive functioning. Further, the sample was homogeneous (white) and 
highly educated. Although the neuropsychological battery used in this study is very 
comprehensive, it must be noted that using digit symbol as part of the executive 
function may be questionable by some neuropsychologists and may pose some 
measurement limitations. However, since many cognitive test overlap in domains, the 
best and most accurate method of measuring overall cognitive function is through the 
use of a global standardized score, as the one presented in this study. It is also 
important to note that the associations of HDL-C with verbal, non-verbal, language or 
executive function measures were not significant, nor were levels of TG associated with 
any other specific cognitive domain. The finding that the composite measure was 
significantly associated with HDL-C while most individual cognitive measures were not 
provides additional evidence that the effect of HDL-C may occur mainly on the global 
level45. This study also lacked data in some important socio-demographic variables 
such as income, medical comorbidities and medications, and 11% of the sample (12 
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people) did not have data regarding APOE ε4 allele status. Finally, sex-specific 
analyses were underpowered. 
 
Conclusion 
The cardiovascular benefits of HDL-C and the detrimental effects of 
hypertriglyceridemia have been known for some time now, but their role in cognitive 
function had not been explored until recent years and is still not well understood. The 
results of this study point to HDL-C as the main lipoprotein associated with cognitive 
performance.  In addition, lipid profile may be more indicative of cognitive functioning in 
women than in men. Moderation by APOE ε4 allele clearly indicates that lipoprotein 
studies need to account for genetics in studies of cognitive function.  
Future Implications. Blood lipid levels are modifiable through simple changes in 
lifestyle habits. Existing cardiovascular research suggests that lowering TGs and raising 
HDL-C can be done relatively easily through a diet containing monounsaturated and 
polyunsaturated fats, exercise, eliminating smoking, reducing alcohol consumption and 
using medications such as niacin, nicotinic acid, statins, fibrates and omega-3 fatty acid 
(fish oil capsules) among others when necessary224,225. Therefore, strategies to maintain 
TG levels low and especially increase HDL-C levels may be a viable population-wide 
intervention strategy to help maintain cognitive function with age. Future research aimed 
at understanding the factors underlying the role of lipoproteins, as well as the sex-based 
differences in the link between lipids and cognition, is needed especially from a life 
course perspective. Additionally, the possibility that boosting HDL-C levels may promote 
cognition should be investigated.  
 64 
 
 
 
CHAPTER 3: STUDY 2: SERUM LIPIDS, HEALTH OUTCOMES AND CHANGE IN 
FUNCTION AMONG OLDER COSTA RICAN ADULTS: THE CRELES STUDY 
 
Abstract 
 
Sustaining physical function into older age is vital for maintaining independence 
and a good quality of life. Decreases in physical function are often associated with 
functional limitations and disability. Furthermore, physical function is often compromised 
by comorbidity in older adulthood. Cardiovascular disease is a main contributor to 
disease burden, limitation of functional abilities and decreased quality of life. However, 
the association between cardiovascular risk factors such as serum lipoproteins and 
physical function in older adults is less clear, especially over time. To date, no previous 
publications were identified in Latino populations. With Latin American countries 
growing older faster than North American or European countries, studying the 
underpinnings of lipoproteins and the pooled effect of risk factors and comorbidity on 
physical function in this group of older adults is necessary.  
This study explored the longitudinal association between baseline total 
cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and 
high-density lipoprotein cholesterol (HDL-C) and physical function. Random effects 
models were used to assess whether lipoprotein levels are associated with subsequent 
change in physical function adjusting for demographics, cardiovascular risk factors and 
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comorbidity.  Results indicated that lower baseline TC and HDL-C scores had cross-
sectional associations with more ADL disability; but not across the three study waves. In 
addition, higher baseline TGs were also associated with better grip strength, but not 
across time. Moreover, there was a significant moderation by cognitive disability on the 
cross-sectional association between TC and ADL disability. Further stratification by 
cognitive disability indicated that the previous association was only significant for 
participants with cognitive disability. Future research should strive to determine if 
maintaining optimal recommended lipid levels delays physical function decline to as 
long as possible. 
 
Introduction 
Physical function is a reflection of health status, the impact of chronic diseases, 
and a crucial determinant of quality of life. It is well known that a decrease in physical 
function leads to functional limitations (e.g., strength, mobility, balance and 
coordination) and disability (e.g., self-reported activities of daily living or instrumental 
activities of daily living) especially among older adults226-231. Moreover, changes in 
physical function may be due to established cardiovascular morbidity. Recent studies 
have shown that cardiovascular disease (CVD) contributes greatly to disease burden 
and decreased quality of life as they are often accompanied by limitation in functional 
abilities86,154. Disruption in lipoproteins such as total cholesterol (TC), low-density 
lipoproteins cholesterol (LDL-C) and high-density-lipoprotein cholesterol (HDL-C) are 
influential factors for atherosclerosis and subsequent complications such as CVD9-11 
and functional decline13,87.  
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With CVD being one of the most common chronic diseases in the old232,233 
understanding the association between lipids and physical function in aging populations 
may be of great importance to maintain healthy functional populations longer. However, 
few studies have explored the association between individual serum lipoproteins and 
physical function altogether44,86,87,137,154,158,234. A small number of longitudinal studies in 
community dwelling older adults have been published examining the relationship 
between lipoproteins and physical function44,234.  Reuben and colleagues investigated 
the effects of albumin and TC in 937 community living adults 70-79 years of age; they 
observed that low serum cholesterol levels over a 3 and 7-year period increased the risk 
of functional decline234. The Longitudinal Aging Study Amsterdam (LASA) is an ongoing 
population-based study looking at changes in physical, cognitive, emotional, and social 
functioning in older adults every 3 years235. An analysis from the LASA study examined 
TC and functional performance decline in adults 55-85 years of age over a 3-year 
change and found that after adjustment for lifestyle and disease-related factors, women 
with lower TC were 2.5 times more likely to decline than women with higher TC (95% 
CI: 1.07-5.84); the association was not observed in men44.  
Recent cross-sectional investigations have also been able to link lower levels of 
TC and HDL-C with mobility limitations and disability. High levels of HDL-C have been 
significantly associated with reduced risk of functional impairment even after accounting 
for other lifestyle-based CVD risk factors (e.g., smoking, exercise) and cardiovascular 
diseases such as stroke or coronary heart disease86,158.  A recent study on adults 60 
years and over found that those with functional limitations and dependence had higher 
TC87.  
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Despite these important findings, research on lipoproteins and physical function 
has been limited and overall ethnically homogeneous. For example, to date no research 
has been found in the literature examining lipids and physical outcomes in a solely 
Latino cohort. Studies with cross-ethnic comparisons have observed that while 
Hispanics living in the United States have less CVD and less cardiovascular mortality 
than non-Hispanic Whites97,236-238, they tend to have a high prevalence of CVD risk 
factors29,51,97,239,240. Hispanics have also been reported to be at a disadvantage in 
physical function as they experience greater disabilities than non-Hispanic Whites in the 
United States241-244.  A recent investigation comparing a physical function questionnaire 
in participants of the Patient-Reported Outcomes Measurement Information System 
(PROMIS®) project found that Spanish speakers with the same underlying conditions 
as English speaking participants reported more physical limitations; this was reflected in 
the fact that Spanish speakers reported 50 of the 114 items of the questionnaire 
differently than English speakers245.  
Although acculturation may play a role in these differences, many underlying 
health factors within each population may account for the differentials. Latinos are often 
collapsed into a single group, but are in fact a heterogeneous group composed of 
multiple ethnicities246. Within-group or nativity differentials are important when 
measuring health behaviors and outcomes246,247. Once within population, or nativity 
differences in Latinos are adequately captured, it may be easier to understand between-
group health differences in the United States or other countries. It has been suggested 
that future studies with ethnically diverse populations need to not only statistically adjust 
for the lack of equivalence in the measures, but also differentiate and stratify their 
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analysis by ethnicity245,248. This way, future public health interventions for the ethnically 
diverse population would be evidence based. 
With a projected 31% Hispanic population in the United States by 2060249 and 
Latin American countries aging faster than North American or European countries250, it 
is extremely important to understand the factors affecting physical function in this group. 
In Costa Rica, for example, 11.5% of the country’s population is expected to surpass 65 
years of age by the year 2025251. With this population aging so quickly, the expected 
economic and social burden to the United States and Latin American countries may turn 
unsustainable.  
Additionally, there are significant sex differences in physical function. It has been 
long described that women experience more disability than males252,253. According to 
results obtained from a 10-year analysis from the National Health Interview Survey, in 
each of all racial-ethnic categories, females had more functional limitations than males 
overall254. A study looking at sex differences in physical health found a significant higher 
number of functional limitations among older women, with the difference increasing with 
age255. One study looking at motor performance in relation to serum lipid characteristics 
in women found that high triglycerides (TG) and low HDL-C showed poor motor skills, 
indicative of functional limitations256. Additionally, Hispanic women tend to have physical 
function more compromised from comorbidity than males250,257. A recent study that 
pooled data from various countries in Latin America and the Caribbean observed that 
women were 1.6 times more likely to have disability in ADLs and 2 times more likely to 
have disability in IADLs compared to Latin men, even after adjusting for age, childhood 
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conditions, adult socio-economic status and current social conditions257. However, with 
such few longitudinal studies, more research is needed to assess the association.  
Moreover, cognitive health is another major determinant of functional abilities. 
Thus cognitive decline/cognitive disability is highly correlated with functional 
decline14,258,259. Results from the Aging, Demographics, and Memory Study (ADAMS) 
found 45% prevalence of IADL limitations in those with cognitive impairment14. 
However, no study was found in the literature associating lipoproteins with both physical 
function and cognitive disability. Additional research is needed to assess this 
relationship.  
Currently, there are many unanswered questions in the association between 
cardiovascular risk factors and physical function across time in older adults. This study 
will contribute to this gap in knowledge in several important ways. First, it will identify the 
lipoproteins associated with disability and functional limitation in older Latino adults. 
Second, the study will pinpoint which cardiovascular risk factors are indicative of 
disability and functional limitations. Third, it may be able to detect which forms of 
comorbidity are directly associated with physical function when accounting for 
demographics and cardiovascular risk factors. Additionally, this study will be the first 
longitudinal study of lipoproteins and physical function among older Latinos, specifically 
Costa Ricans a population yet to be explored in this respect. Understanding the 
relationship between lipids and physical function and determining which lipids are key in 
older ages, may help clinicians suggest treatment needs and anticipate treatment 
response specific to this aging Latino population.  
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Research Aims 
The current study had two aims. The first aim explored the association between 
baseline TC, LDL-C, TG and HDL-C and decline in physical function over time. The 
second aim examined if sex and cognitive disability moderated either of the 
associations. The population-based study from Costa Rican Longevity and Healthy 
Aging Study (CRELES) was used for this analysis. Based on previous studies, it was 
hypothesized that those older adults with sustained lower levels of TC, LDL-C and HDL-
C and high levels of TG over the study period will have more physical function decline 
(more functional limitations and disability) even after adjusting for demographics and 
possible confounders. It was expected that being female and having cognitive disability 
would moderate the association between the lipoproteins and physical function. 
Aim 1. The main purpose of this study was to determine if baseline measures of 
independent lipoproteins TC, LDL-C, TG and HDL-C are associated with change in 
physical function taking into account demographics, cardiovascular risk factors and 
comorbidity in adults over the age of 60 participating in the CRELES. Physical function 
measured as (a) disability and (b) functional limitations. 
Hypothesis 1. It was hypothesized that those older adults with lower baseline 
levels of TC, LDL-C and HDL-C and high levels of TG would have worse physical 
function decline (more disability and functional limitations) over the study period even 
after adjusting for demographics and possible confounders.  
Aim 2. The second aim was to investigate whether sex and/or cognitive disability 
moderated any statistically significant association between baseline lipoproteins (TC, 
LDL-C, TG and HDL-C) and change in physical function over time.  
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Hypothesis 2. It was hypothesized that sex and/or cognitive disability would 
moderate any statistically significant association between each independent lipoprotein 
and physical function. Specifically, it was also hypothesized that the association 
between lipoproteins and physical function would differ between men and women; with 
the expectation that physical function decline would be more prevalent among women. 
It was also hypothesized that the association between lipoproteins and physical function 
would be significant only among participants with cognitive disability. 
 
Methods 
 
This study included all three waves of data collection from CRELES. A total of 
2,827 residents of Costa Rica aged 60 and older in 2005 (oversample with the oldest 
old) were initially included in the first wave of the study between November 2004 and 
September 2006260. The initial CRELES sample was selected based on the 2000 
census database using a multistage sampling design and complemented with a 100% 
sample of near centenarians and centenarians260. Lost to follow-up between wave 1 and 
2 was 7%. Wave 2 includes all 2,364 participants that were still alive and were willing to 
participate between October 2006 and July 2008. There was a 16% attrition rate at 
wave 2 (10% deceased, 6% could not be located). Details of the study design, sampling 
distribution, weights, and non-response rates for waves 1 and 2 can be found 
elsewhere260,261. The third wave took place from February 2009 to January 2010. There 
are 1855 surviving and completed interviews; loss of follow up between waves 2 and 3 
thus represented 9% of the baseline sample and there was 10% attrition of the wave 2 
sample262. On average, a quarter of the interviews were conducted using proxies at all 
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three waves; 95% of the sample provided blood samples and 91% had anthropometric 
measures. Figure 10 shows the study composition used in this analysis.  All individuals 
consented underwent in person interviews conducted by trained personnel. The 
“Committee on Science and Ethics” of the University of Costa Rica approved the 
CRELES study. The three waves were approved March 17, 2004 in session reference 
VI-763-CEC-23-|-04. The databases are completely anonymous (name and other 
identifiers were removed). 
 
Measures 
Demographic variables were obtained from each participant at the time of initial 
interview. For this analysis, age was analyzed as a continuous variable. Sex was 
categorized as males=1 and females=2. Education was coded continuously as the 
highest year of schooling achieved.  Socioeconomic status was measured through 
perceived economic situation, participants were asked to describe their current 
economic situation; this was measured and coded in the following scale: 1=Excellent, 
2=Very good, 3= Good, 4=Average/Normal, 5=Poor or 9=Did not know or did not 
respond.   
 
Dependent Variables 
Physical function for older adults was assessed through measures of physical 
limitations and disability. Functional measures of physical limitation included (a) 
maximum grip strength, (b) ability to stand with no arms, which measures balance and 
equilibrium and (c) the time-up and go test, or walking ability. Grip strength was 
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assessed having the participant sit for at least 3 minutes before doing the first 
measurement on the dominant hand using a Creative Health Products Inc. 
dynamometer, model T-18260. Participants were asked to stand with dominant arm 
extended beside their body, the first measurement was taken; and then sit again for 
another 3 minutes before the second measurement was taken. Two measures were 
obtained but only the highest whole value of the dominant hand is used in this analysis. 
This method has been previously used in epidemiological studies263.  
For mobility assessments, participants were asked if they had any impairment 
from doing a mobility and flexibility test, if the response was negative the measures for 
flexibility and mobility were obtained to quantify equilibrium and balance, and walking 
ability. All mobility assessments were coded 1=able to complete, 2=tried but unable, 
and 3= those that could not performed the test or refused. Similar coding has been 
previously used in the literature234,264. The description of each functional test is as 
follows: (a) equilibrium and balance were assessed asking the participant to remain 
standing with feet together for 10 seconds and to stand up five times from a sitting 
position with arms crossed on the chest260; (b) walking was measured by asking the 
participant to rise off a chair (from a sitting position) and walk a distance of 3 meters at 
normal walking speed. The variable is known as the Timed Up and Go Test (TUG) test 
and was coded as stated above.  
Self-reported disability was coded as suggested in the literature155 and measured 
in the study using ADL and IADLs. ADLs included walking, bathing, eating, going to 
bed, using the toilet, and grooming. IADLs comprised preparing food, managing money, 
shopping, and managing medications. For general comparisons of the data each  
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Figure 10. Study Flow Chart of All Waves Included in the Analysis for Study 2. 
 75 
ADL/IADL was categorized as: 1=No, I never need help; 2=Yes, I have difficulty but can 
do without help; 3=Yes, I have difficulty and need help; and 4=Never do or cannot do 
the activities. Disability was coded following the International Classification of 
Functioning, Disability and Health (ICF)155,265 as either 1=no self-reported difficulty or 
limitation or 2=had some degree of difficulty or could not do the activity. If the subject 
reported one or more limitation in ADL or IADL then the subject was labeled as being 
disabled or having ADL disability or IADL disability in that given category. This 
dichotomized classification is clinically applicable and has been previously used in 
similar analyses86. For the statistical model analysis, the summary score (continuous 
variable) for ADLs and IADLs were included in the models as previously done in the 
literature266. The score for ADLs ranged from 0 to 20 and for IADLs from 0 to 24 in the 
study period, with 0 indicating no disability on any of the ADL/IADL domains. 
Independent Variables 
Blood samples for lipoproteins were measured from fasting serum the day after 
the baseline interview. All blood specimens were collected after a 14-hour fasting period 
in participants’ homes by venipuncture, normally during the second visit (the day after 
the main interview) and sent immediately to the participant laboratories for analysis. 
Three tubes of blood samples were collected: one was a vacutainer with (EDTA) of 
approximately 3-4 ml which was centrifuged later to separate the plasma of the cells 
and two 5 milliliter tubes were vacutainers without anticoagulant (SST) with coagulum 
activator for obtaining serum. A fraction of the serum was separated in a conical tube 
type Eppendorf to obtain the measures for the TC, LDL-C, TG, HDL-C and 1 ml of 
complete blood in the tube EDTA for the analysis of glycosylated hemoglobin. Additional 
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specific protocol for laboratory samples and quality control measures can be found 
elsewhere260. Specific levels of lipoproteins TC, LDL-C, TG, and HDL-C were also 
examined and converted to mmol/l for comparison with previous studies using the 
standard international measurement system. 
  Covariates. Cardiovascular risk factors included in this study were based on 
definitions suggested by the American Heart Association56. Covariates for comorbidity 
included here were those known to correlate with both cardiovascular disease and 
physical function. 
 Hypertension. Sitting systolic and diastolic blood pressure was measured twice 
during the interview and the average reading was used. If the participant had systolic 
≥140 mmHg, or diastolic ≥90 mmHg, or they reported being diagnosed with 
hypertension, taking antihypertensive and/or diuretic medication, they were 
categorized as having hypertension (hypertension=1), otherwise hypertension=0. 
 Antihyperlipidemics. This variable was dichotomized as: 1= the participant was 
taking medications to lower cholesterol; 0=the participant said no or do not know.  
 Diabetes. Accounted for by including the participant’s levels of glycosylated 
hemoglobin (HbA1c) in mg/dl to cover those with high glucose levels that did not 
know they were diabetics.  
 Smoking status. Coded (0) never smoked, (1) previous smoker or (2) current 
smoker.  
 Self-report Exercise. Participants were asked if in the last 12 months they exercised 
regularly or did other physically rigorous activities like sports, jogging, dancing, or 
heavy work, 3 times per week. If they answer yes, exercise=1, otherwise exercise=0.  
 77 
 Chronic health conditions known to add to the burden of functional limitations and 
disability are included in the analysis. These comprised current or medical history of: 
 Heart disease. If participants were ever told by a physician they had heart disease 
with or without myocardial infarction, then coronary heart disease was marked 
positive (CHD=1), otherwise CHD= 0.  
 Stroke. Coded as 1 if participants were ever told by a physician they had a stroke or 
0 if not, or they did not know. 
 Arthritis. If in the last 2 years participants were told by a physician they had arthritis, 
rheumatism or arthrosis, then arthritis=1, otherwise arthritis=0.  
 Osteoporosis. If in the last 2 years participants were told by a physician they had 
osteoporosis or frail bones, then osteoporosis=1 or if the participant said no or did 
not know, then osteoporosis=0. 
 Pulmonary pathology. If in the last 2 years participants were told by a physician of 
having a respiratory disease or chronic pulmonary disease (emphysema, 
tuberculosis, asthma or chronic bronchitis), then the variable was coded as lung=1, 
otherwise lung=0. 
 Cancer. If in the last 2 years participants had been told they had cancer or a 
malignant tumor, not inclusive of small skin tumors, then cancer=1; otherwise 
cancer=0. 
 Psychiatric conditions. If in the last 2 years participants were told by a physician they 
had any nervous or psychiatric problems such as depression, then 
psych=1,otherwise psych=0. 
 78 
 Insomnia. This dichotomized variable, participants were asked if in the last 12 
months they have or had any problems with insomnia. If they answer positively 
insomnia=1, otherwise insomnia=0. 
 Severe cognitive disability. This variable was coded as a categorical value, 
where 0 meant not having a cognitive disability and 1 stated that the participant 
had severe cognitive impairment determined by a short modified Spanish version 
of the MMSE with a maximum of 15 points. The participant was coded as having 
severe cognitive if the participant scored less than or equal to 11 items 
incorrectly (4/15 questions correct). 
 
Statistical Analysis 
Random effects modeling (REM), also known as mixed-effects or multilevel 
models267, were performed utilizing SAS software, version 9.4 (Copyright © 2002-2012 
SAS Institute Inc., Cary, NC). Mixed models have the ability to measure and account for 
random variability in scores that can ultimately bias results268,269.  The means are 
modeled by fixed effects (identical for all individuals) and the residuals and variances by 
random effects270. REMs share some basic characteristics with repeated measures 
analysis of variance (rANOVA); however, mixed models have a number of advantages. 
First, REM include all individuals for whom complete data is not available268. Second, 
rANOVA treats time as a categorical variable, while multilevel growth curves treat time 
as continuous, which better reflects reality270. Third, REM also has the advantage that 
individuals are assumed to follow a curve shape but can vary in the parameters 
(random effects)270.  
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This study first examined baseline demographics at wave 1 and presented them 
separately for males and females. Participant’s characteristics were also analyzed 
comparing them to each study outcome by wave. Gender characteristics were analyzed 
by independent samples t-test and Pearson chi-square test. Continuous variables were 
reported as means with standard deviation (SD) and were compared using the t-test.  
Pooled p-values were used for equal variances and Satterthwaite for unequal variances. 
Categorical variables were analyzed using Chi-square test for equal proportions. 
Pearson correlation coefficients were also obtained for all dependent and independent 
variables.  
REM was used to examine lipoproteins TC, LDL-C, TG and HDL-C at baseline in 
relation to physical function and change in function over three measurement occasions 
while taking into account demographics, cardiovascular risk factors and comorbidity. 
The equilibrium and TUG variables were explored in the descriptive analysis, but most 
of values were zero, not allowing us to use inferential statistics on these two variables. 
Therefore, to study the association between lipids and physical function outcomes, ADL 
disability, IADL disability, and grip strength were utilized as the outcomes. Each 
outcome was analyzed separately for each of the lipids. The REMs estimate overall 
fixed effects, or average effects for the group, as well as random effects, which are 
reflective of the person’s deviation from the fixed effect. Random effects were calculated 
using an unstructured correlations matrix, the most commonly used matrix for these 
types of data, and included the baseline outcome/physical function (intercept) and rate 
of decline (slope). All study covariates were included in the main models, which also 
provided the best model fit. At level 1, an individual’s development is represented by 
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each person’s growth trajectory (within-person model) with an intercept (X0i) and a slope 
(β1i); it provides information on whether participants changed over time. Level 2 
represents the inter-individual change in linear time (across waves 1, 2 and 3). The 
three study waves were coded as an ordinal variable with wave 1 coded as time zero. 
Continuous variables were grand-mean centered. Dichotomous variables were contrast 
centered (i.e., -1 vs. 1) as suggested271. The alpha levels used for the analysis was 
p<.05. 
The REMs were estimated as two-level models. For example, in the case of ADL 
as the outcome, the level 1 intra-individual change in predictors is based on an 
individual’s baseline ADL score (Yij ) as a function of the average ADLs across all 
participants at baseline, X0i  (or fixed effect), the average group difference in the 
lipoproteins and demographic variables for the ADLs. These estimates provide the 
cross-sectional association between the predictor and ADL scores. At level 2, the model 
estimates if there are significant inter-individual differences in change of ADLs after 
controlling for variables of interest. In other words, level 2 describes the average rate of 
change of ADLs over time or longitudinally (random effect of how the individual varies 
around the mean ADL) and how it is systematically related to the predictor variable(s) 
being tested. The equation used was as follows: 
 
Yij = X0i + β1i (Time) + β2i (Lipoprotein) + β3i (Time*Lipoprotein) + β4i (Age) + β5i 
(Age*Time) + β6i (Sex) +   β7i (Sex*Time) + β8i (Education) + β9i (Education*Time) + β10i 
(Perceived economic situation) + β11i (Perceived economic situation*Time) + 
β12i(Hypertension) + β13i(Hypertension*Time) + β14i(Antilipidemics) + 
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β15i(Antilipidemics*Time) + β16i(Glycated hemoglobin) + β17i(Glycated hemoglobin*Time) 
+ β18i(Smoking) + β19i(Smoking*Time) + β20i(Exercise) + β21i(Exercise*Time) + 
β22i(Coronary heart disease) + β23i(Coronary heart disease*Time) + β24i(Stroke) + 
β25i(Stroke*Time) + β26i(Arthritis) + β27i(Arthritis*Time) + β28i(Osteoporosis) + 
β29i(Osteoporosis*Time) + β30i(Pulmonary) + β31i(Pulmonary*Time) + β32i(Cancer) + 
β33i(Cancer*Time) + β34i(Psychiatric) + β35i(Psychiatric*Time) + β36i(Insomnia) + 
β37i(Insomnia*Time) + β38i(Cognitive disability) + β39i(Cognitive disability*Time) + bi + εij 
 
where Y represents the outcome (physical function) for the ith subject during the jth 
observation. The X0i is the intercept (when a participant’s value on the predictors are 
both zero), β1i the slope (time representing the wave of the study), which is the 
difference between the observed measure of the outcome and the expected measure of 
the outcome based on the model. The within-person slope (βij) is the fixed effect for the 
lipoproteins and demographics and bi is the subject-specific random effect that allows 
for the baseline value of the predictor to vary for each subject and the εij is the within-
subject error term. 
To test the second aim, interaction terms for sex and cognitive disability were 
performed for all statistically significant lipoproteins in the first aim. Further, stratification 
was done for those statistically significant interactions.  
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Results 
 
Sample Characteristics 
Baseline characteristics of the sample with complete variables of interest are 
presented in table 11. The mean age of the sample was 76.4 (SD10.2), with 4th grade of 
elementary school being the average grade completed. Half of the sample self-reported 
their health as better than good, 41% thought it was average and only 9% thought their 
health was bad. Most thought their perceived economic situation was average or better. 
Most of the participants owned their home (84%); 60% reported residing in an urban 
area. 
Over half of the sample at baseline had never smoked and only 8% were current 
smokers. Most did not exercise regularly (76%), but men were more physically active 
than women.  Figure 11 shows the sample’s lipid distribution. Levels were on the 
borderline high category for TC, LDL-C and TG32,33. Refer to table 1 for lipid ranges. 
The mean blood pressure for the sample was 145.9/82.6 mmHg, which is considered to 
be hypertensive for younger older adults, but in target values for those between 70-90 
years of age272,273.  Women had significantly more hypertension than men. The 
percentage of glycated hemoglobin for the sample was 5.8% and it was in the normal 
range (4.0-6.0%). Women had significantly higher levels of HbA1c. With the exception 
of myocardial infarctions, women had significantly more comorbidities than men. An 
important 44.3% of older adults reported sleeping problems and almost a quarter (23%) 
were reported to have cognitive disability. There were no differences in the percentage 
of stroke or cancer between males and females.  
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Physical function was examined through ADL/IADLs and grip function in the REM 
models, but a description of equilibrium, and the TUG test is also provided. When 
disability was examined at baseline, it was found that 56% of participants did not report 
any problems with ADLs such as bathing, eating, going to bed, using toilet, or grooming. 
However, of those that did report problems, 60% had difficulty with walking, 44% with 
grooming and 15% problems bathing. Three quarters of the sample did not report 
problems with IADLs, but disabilities presented included: shopping (33%), managing 
medications (25%), preparing food (24%), and managing money (21%). Those with ADL 
and IADL disabilities were on average 11 years older (p’s<.001); less educated (ADLS 
p=.002; IADLs p=.004); and had significantly lower levels of TC and LDL-C (p’s<.001). 
 
 
 
Figure 11.  Box-plots of Lipoprotein Range in the Sample. 
Note: TC=total cholesterol; LDL=low-density lipoprotein cholesterol; TG=triglycerides; HDL-C= high-density 
lipoprotein cholesterol 
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Table 11. Baseline Characteristics of Participants by Gender. 
 Total Sample 
(N=2677) 
100% 
Males 
(n=1227) 
45.8% 
Females 
(n=1450) 
54.2% 
p-
value 
Mean Age (SD)  76.4 (10.2) 76.4 (10.3) 76.4 (10.2) .869 
Mean Education (SD)  3.7 (1.8) 3.7 (1.8) 3.7 (1.7) .382 
Perceived Current Economic Situation 
Excellent 
Very Good 
Good  
Average/Normal 
Poor 
Do not know/No response 
88(3.2) 
156 (5.8) 
792 (29.6) 
1231 (46.0) 
402 (15.0) 
8 (0.3) 
40 (3.3) 
67 (5.5) 
319 (26.0) 
587 (47.8) 
211 (17.2) 
3 (0.2) 
48 (3.3) 
89 (6.2) 
473 (32.6) 
644 (44.4) 
191 (13.2) 
5 (0.3) .002 
Mean Lipoprotein Levels mmol/l (SD) 
Total Cholesterol 
LDL-C* 
Triglycerides  
HDL-C* 
5.5 (1.3) 
3.5 (1.1) 
1.8 (1.0) 
1.2 (0.3) 
5.3 (1.2) 
3.4 (1.0) 
1.7 (1.0) 
1.1 (0.3) 
5.7 (1.3) 
3.7 (1.1) 
1.8 (1.0) 
1.2 (0.3) 
<.001 
<.001 
.001 
<.001 
Cardiovascular Risk Factors 
Mean Systolic Blood Pressure mmHg (SD) 145.9 (24.7) 144.6 (24.0) 147.0 (25.3) .012 
Mean Diastolic Blood Pressure mmHg  (SD) 82.6 (12.8) 81.8 (12.8) 83.2 (12.7) .007 
Have Hypertension % 49.0 41.4 55.5 <.001 
Taking Medications for Hypertension % 45.5 39.3 50.7 <.001 
Taking Diuretics % 23.3 20.2 25.9 <.001 
Hypercholesterolemia % 34.5 27.3 40.6 <.001 
Taking Medication for Hypercholesterolemia % 18.7 15.5 21.5 <.001 
Diabetics 19.3 15.3 22.8 <.001 
Glycated Hemoglobin (HbA1c) %  5.8 (1.1) 5.7 (1.0) 5.9 (1.2) <.001 
Exercise % 24 32.6 16.8 <.001 
Smoking % 
Current Smoker 
Previous Smoker 
Never Smoked 
8.1 
35.1 
56.8 
13.6 
54.5 
31.9 
3.2 
18.5 
78.2 
<.001 
Comorbidity % 
Stroke 5.4 5.1 5.6 .547 
Myocardial Infarction 5.3 6.2 4.5 .009 
Pulmonary Problems 18.0 14.9 20.6 <.001 
Cancer 6.8 6.3 7.2 .273 
Arthritis 16.6 12.3 20.6 <.001 
Osteoporosis 9.4 2.0 15.6 <.001 
Psychiatric (nervous problems) 18.6 12.3 24.0 <.001 
Insomnia 44.3 37.5 50.4 <.001 
Cognitive Disability 22.7 250 (20.4) 348 (24) .026 
Note: *LDL-C=Low-density lipoprotein cholesterol, HDL-C=High-density lipoprotein cholesterol; SD=Standard 
Deviation. Optimal range: Total Cholesterol< 5.2mmol/l; LDL-C<3.4mmol/l; Triglycerides<1.7mmol/l; HDL-C 
≥1.5mmol/l  
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When looking at the associations between disability and functional limitations, 
those with ADL and IADL disabilities had significantly more difficulty with equilibrium 
(standing with no arms) and walking (TUG test) (p’s<0.001). Table 12 shows participant 
characteristics with respect to physical function status for the overall sample and by sex. 
Females had significantly more ADL disability than males (p<0.001) and more functional 
limitations in grip strength (p<.001) and equilibrium (p=0.001); the sex difference was 
not significant for IADLs (p=0.251) and for the TUG (p=0.344).  
 
 
Table 13 presents the baseline lipid and HbA1c levels by disability. Overall, 
participants with ADL disability had lower TC, LDL-C HDL-C and higher HbA1c than 
those without ADL disabilities; while those with IADL disabilities had lower TC, LDL-C 
Table 12. Participant Characteristics at Baseline for Physical Function by Sex. 
 
 Disability and/or Functional Limitation % 
 Total Sample 
(N=2677) 
100% 
Males 
(n=1227) 
45.8% 
Females 
(n=1450) 
54.2% p-value 
Mean Disability in Activities of Daily Living 
(SD) 
8.5 (3.4) 8.1 (3.3) 8.8 (3.5) <.001 
Mean Disability in Instrumental Activities 
of Daily Living (SD) 
6.2 (3.2) 6.1 (3.3) 6.2 (3.1) .244 
Mean Grip Strength (SD) 22.3 (8.6) 27.8 (8.0) 17.5 (5.7) <.001 
Equilibrium 
Able and completed 
Tried but unable 
Not attempted/refused 
2068 (91.7) 
61 (2.7) 
126 (5.6) 
982 (94.0) 
17 (1.6) 
46 (4.4) 
1059 (89.7) 
43 (3.6) 
79 (6.7)  
Time up and go test 
Able and completed 
Tried but unable 
Not attempted/refused 
2233 (99.0) 
4 (0.2) 
18 (0.8) 
1038 (99.3) 
1 (0.1) 
6 (0.6) 
1166 (98.7) 
3 (0.3) 
12 (1.0)  
Note: SD=Standard Deviation 
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and TG than those without IADL disabilities. Older adults with cognitive disability had 
lower levels of TC, LDL-C, TG and HbA1c, but surprisingly had slightly higher HDL-C. 
Results also indicated that older adults with disabilities have lower lipid levels than 
those without disabilities. 
 
Correlations 
 A Pearson correlation analysis was performed to first observe and better 
understand the data; second, to examine whether the dependent variables and 
covariates were associated; and last to determine the strength of the associations. As 
illustrated in table 14, older age was significantly correlated with lower levels of TC, 
LDL-C and TG, but with higher levels of HDL-C. Being a woman was associated with 
higher level of lipids, specifically significant were TC, TG and HDL-C. Education and 
perceived economic situation did not correlate with any of the lipoproteins of interest.  
Table13. Baseline Lipid Characteristics by Disability Status. 
 
 ADL disability IADL disability Cognitive Status 
 Without 
disability 
With disability Without 
disability 
With disability Without 
cognitive 
disability 
With cognitive 
disability 
 
Mean 
(SD) 
Mean 
(SD) 
p Mean (SD) 
Mean 
(SD) 
p Mean (SD) Mean (SD) p 
TC* 5.6 (1.2) 5.4 (1.3) <.001 5.6 (1.3) 5.3 (1.3) <.001 5.6 (1.3) 5.3 (1.3) <.001 
LDL-C* 3.6 (1.1) 3.4 (1.1) <.001 3.6 (1.1) 3.4 (1.1) <.001 9.7 (29.5) 6.8 (20.8) <.001 
TG* 1.8 (1.0) 1.8 (1.0) .592 1.8 (1.0) 1.7 (1.0) .001 1.8 (1.0) 1.6 (0.9) <.001 
HDL-C* 1.2 (1.1) 1.1 (1.1) .123 1.1 (0.3) 1.2 (0.4) .165 1.1 (0.3) 1.2 (0.4) <.001 
HbA1C** 5.7 (1.1) 5.9 (1.2) <.001 5.8 (1.1) 5.9 (1.2) .131 5.8 (1.2) 5.7 (1.0) <.001 
 
Note. *Optimal range: Total Cholesterol (TC) < 5.2mmol/l; Low-density lipoprotein cholesterol (LDL-C) <3.4mmol/l; 
Triglycerides (TG) <1.7mmol/l; High-density lipoprotein cholesterol (HDL-C) ≥1.5mmol/l; P-values are based on t-test 
statistics. SD= Standard deviation. 
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When cardiovascular risk factors were examined, having high levels of HbA1c, 
being hypertensive and taking medication for cholesterol was associated with higher 
levels of LDL-C, TG and low levels of HDL-C. People who did not exercise were linked 
with higher levels of TC and lower HDL-C, while smoking was linked with lower levels of 
both TC and HDL-C. When comorbidities were assessed, having had a stroke 
correlated with higher levels of LDL-C. In general, those with a history of osteoporosis 
or depression had higher levels of TC and HDL-C. Lower levels of TC, LDL-C and TG 
and higher levels of HDL-C were linked with cognitive disability.  
 
Table 14. Correlations between Lipoproteins, Demographic Characteristics, 
Cardiovascular Risk Factors and Comorbidities. 
 
 TC LDL-C TG HDL-C 
Age -0.11*** -0.06** -0.13***  0.08*** 
Sex  0.18***  0.02  0.06**  0.21*** 
Max Education Achieved -0.02  0.02  0.03  0.01 
Perceived Economic Situation -0.04  0.01 -0.01  0.00 
HbA1c 0.01 0.05* 0.19*** -0.13*** 
Hypertension -0.004 0.05** 0.09*** -0.08*** 
Cholesterol Medications -0.01 0.07*** 0.13*** -0.06** 
Exercise 0.04* 0.01 0.04 -0.05** 
Smoking -0.05* 0.01 0.01 -0.08*** 
CHD  -0.04 -0.01 0.003 -0.02 
Stroke -0.03 0.04* 0.01 -0.02 
Rheumatoid Arthritis  -0.01 0.02 -0.003 0.03 
Osteoporosis 0.06*** 0.0003 0.02 0.07*** 
Pulmonary Pathology (e.g. COPD) 0.01 -0.01 0.001 0.01 
Cancer -0.001 0.02 0.03 -0.01 
Psychiatric (e.g. Depression) 0.04* -0.01 0.01 0.07*** 
Insomnia 0.01 0.01 -0.001 0.03 
Cognitive disability -0.10*** -0.05* -0.09*** 0.05* 
Note: <.05*, <.01**, <.001*** TC=Total cholesterol, LDL-C=Low-density lipoprotein cholesterol, TG=Triglycerides, 
HDL-C=High density-lipoprotein cholesterol. 
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Table 15 shows the correlations between the lipoproteins and functional 
outcomes. At baseline, lower levels of TC correlated with increased ADL/IADL disability. 
Lower levels of LDL-C were related to more IADL disability. Lower TG were significantly 
associated with more disability overall and lower HDL-C was related to lower grip 
strength. However, by the third wave only lower levels of HDL-C correlated with an 
outcome (grip strength). 
 
Table 16 displays the correlation analysis of the association between 
demographics and functional outcomes. At baseline, age and education were 
significantly related to all functional outcomes examined. Older ages were associated 
with more ADL and IADL disability and lower grip strength. Sex (being female) was also 
related to more ADL disability and lower grip strength. Higher education was associated 
Table 15. Correlations between Functional Outcomes and Lipoproteins by Wave. 
 ADL IADL Grip 
Wave 1    
TC -0.11*** -0.10*** -0.04 
LDL-C -0.01 -0.04* 0.02 
TG -0.07*** -0.09*** 0.03 
HDL-C  0.01  0.04* -0.17*** 
Wave 2    
TC -0.07*** -0.06** -0.08*** 
LDL-C -0.03 -0.04* -0.002 
TG -0.06** -0.09*** 0.03 
HDL-C  0.03  0.05* -0.21*** 
Wave 3    
TC -0.05 -0.04 -0.02 
LDL-C -0.003 -0.02 -0.002 
TG -0.02 -0.03 -0.0004 
HDL-C  0.04  0.04 -0.09*** 
Note: <.05*, <.01**, <.001*** TC=Total cholesterol, LDL-C=Low-density lipoprotein cholesterol, TG=Triglycerides, 
HDL-C=High density-lipoprotein cholesterol, ADL=Activities of daily living, IADL=instrumental activities of daily 
living. 
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with better grip strength, while lower levels of education achieved were related to more 
ADL/IADL disability. Higher income correlated with more reported ADL and IADL 
disability. 
 
 
The association between the functional outcomes and cardiovascular risk factors 
is illustrated in table 17. Hypertension was associated with lower grip strength 
throughout the study. Taking medications for cholesterol was related to less difficulty 
with IADLs in at waves 1 and 2. Exercise correlated to all outcomes at baseline, such 
that not exercising was associated with more ADL/IAD disability. Furthermore, those 
who did exercise performed better in grip function throughout the study. 
Table 16. Correlations between Functional Outcomes and Demographics by Wave. 
 ADL IADL Grip 
Wave 1    
Age  0.47***  0.54*** -0.43*** 
Sex  0.10***  0.02 -0.60*** 
Max Education Achieved -0.04* -0.12*** 0.08*** 
Perceived Economic Situation  0.10***  0.12*** -0.01 
Wave 2    
Age  0.48***  0.56*** -0.42*** 
Sex  0.11***  0.04* -0.60*** 
Max Education Achieved -0.04 -0.11*** 0.08*** 
Perceived Economic Situation  0.05*  0.08*** -0.01 
Wave 3    
Age  0.47***  0.51*** -0.23*** 
Sex  0.14***  0.05* -0.42*** 
Max Education Achieved -0.07* -0.12*** 0.07** 
Perceived Economic Situation  0.10***  0.09*** 0.01 
Note: <.05*, <.01**, <.001*** Note: TC=Total cholesterol, LDL-C=Low-density lipoprotein cholesterol, TG=Triglycerides, 
HDL-C=High density-lipoprotein cholesterol. 
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Table 18 shows the relationship between functional outcomes and comorbidities. 
All comorbid conditions were significantly associated with more ADL disability 
throughout the study waves. With the exception of osteoporosis, IADLs were also 
associated with all comorbidities. Lower grip strength was associated with the majority 
of comorbidity in the first two study waves. 
Table 17. Correlations between Functional Outcomes and Cardiovascular Risk 
Factors by Wave. 
 ADL IADL Grip 
Wave 1    
HbA1c  0.004 -0.003 -0.04 
Hypertension -0.01 -0.03 -0.05* 
Cholesterol Medications -0.03 -0.07** 0.02 
Exercise -0.27*** -0.28*** 0.29*** 
Smoking -0.07*** -0.01 0.28*** 
Wave 2    
HbA1c  0.04*  0.001 -0.05* 
Hypertension  0.04  0.01 -0.05* 
Cholesterol Medications -0.02 -0.08*** 0.01 
Exercise -0.26*** -0.26*** 0.26*** 
Smoking  -0.07** -0.001 0.26*** 
Wave 3    
HbA1c  0.06*  0.002 -0.05* 
Hypertension  0.06**  0.03 -0.07** 
Cholesterol Medications -0.03 -0.05* -0.01 
Exercise -0.26*** -0.23*** 0.15*** 
Smoking -0.07**  0.01 0.21*** 
Note: <.05*, <.01**, <.001*** ADL=Activities of daily living, IADL=instrumental activities of daily living, 
HbA1c=hemoglobin A1c. 
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Table 18. Correlations between Functional Outcomes and Comorbidities by Wave. 
 ADL IADL Grip 
Wave 1    
CHD  0.08***  0.07*** -0.06** 
Stroke 0.24***  0.21*** -0.11*** 
Rheumatoid Arthritis  0.11***  0.04* -0.13*** 
Osteoporosis 0.06** -0.01 -0.13*** 
Pulmonary Pathology (e.g. COPD) 0.09***  0.06** -0.08*** 
Cancer 0.08***  0.05** -0.05** 
Psychiatric (e.g. Depression) 0.08***  0.06** -0.10*** 
Insomnia 0.12***  0.09*** -0.14*** 
Cognitive disability 0.58***  0.71*** -0.34*** 
    
Wave 2    
CHD  0.06**  0.07*** -0.05* 
Stroke 0.22***  0.19*** -0.10*** 
Rheumatoid Arthritis  0.10***  0.06** -0.16*** 
Osteoporosis 0.05* -0.001 -0.15*** 
Pulmonary Pathology (e.g. COPD) 0.09***  0.07** -0.09*** 
Cancer 0.06**  0.08*** -0.04 
Psychiatric (e.g. Depression) 0.08***  0.06** -0.09*** 
Insomnia 0.10***  0.09*** -0.16*** 
Cognitive disability 0.56***  0.71*** -0.29*** 
    
Wave 3    
CHD  0.11***  0.10*** 0.01 
Stroke 0.20***  0.18*** -0.02 
Rheumatoid Arthritis  0.16***  0.07** -0.05* 
Osteoporosis 0.07** -0.005 -0.13*** 
Pulmonary Pathology (e.g. COPD) 0.07**  0.09*** -0.04 
Cancer 0.05*  0.07** -0.01 
Psychiatric (e.g. Depression) 0.08**  0.06** -0.11*** 
Insomnia 0.12***  0.08*** -0.09*** 
Cognitive disability 0.46***  0.51*** -0.08** 
Note: <.05*, <.01**, <.001*** ADL=Activities of Daily Living, IADL=Instrumental Activities of Daily Living, 
CHD=Coronary Heart Disease. 
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Random Effect Model (REM) Results 
Intraclass correlations (ICCs) were calculated for ADLs, IADLs, and grip strength 
to find out whether there was a sufficient amount of within- and between-person 
variance in the three outcomes to conduct the REM, as suggested previously 274. 
Between-person variance (expressed as ICC value) indicates how much participants 
vary in their actual outcome scores. For example, a low value for between-person 
variance would mean that participants have about the same functional limitations. 
Within-person variance (expressed as 1-ICC value) indicates how much participants 
vary with respect to each participant’s trajectory of change. Low values for within-person 
variance would indicate that participants change in about the same way (e.g., all decline 
at about the same rate) across the three measurement occasions.  The ICC results 
suggested that 70% to 72% of the total variance was due to between-person variance.  
The 1-ICC results suggested that 28% to 30% was due to within-person variance.  
To assess whether TC, LDL-C, TG and HDL-C were associated with functional 
outcomes, REM models for each dependent variable were estimated adjusting for 
demographics, cardiovascular risk factors, and comorbidity. Table 19a-19d presents the 
results of the REM analyses for all three outcome variables of interest. The fixed effect 
for each of the intercepts represents the average baseline outcome score. The fixed 
effect for time represents average change in the outcome per one wave. The fixed 
effect for predictor shows the average change in the outcome per one unit change in the 
predictor. The fixed effect for the time by predictor interaction shows the average 
change in the outcome per wave when the value of the predictor increases by one unit.  
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REM Results for Intercept and Slope. To summarize, the results for the 
intercept (the average value for the outcome at baseline when controlling for all 
independent variables in the model) and the slope (the average change in the outcome 
scores per one wave, controlling for all independent variables in the model) are first 
discuss. For ADLs, the average value at baseline after adjusting for all covariates (e.g., 
the intercept) was consistently above 4 for all lipoproteins. There was not a significant 
change in ADLs such that the ADL scores increased by an average of just under 0.06 
points with each wave. For IADLs, the average covariate adjusted scores at baseline 
were almost 3.8 for all lipids, and the participants IADL score declined on average by 
about additional 0.09 points per wave, but this decrease was also not significant. For 
grip, the average adjusted baseline scores were around 39 and these scores did not 
change significantly across the three waves.   
REM Results for Random Effects. This section summarizes the results for 
random effects (i.e., the variability in scores at the intercept and in change over time, as 
well as covariance between the scores at the intercept and over time) across the 
reported models. The significant random effects for the variance in the intercept across 
all outcome models indicated that baseline outcome scores varied significantly, 
providing a good reason to use REM (where adjustment for the potential effect of 
baseline values on subsequent trajectory of change is incorporated). The significant 
variance of time demonstrated that there were significant individual differences in the 
rate of change for disability and functional limitations.  In other words, participants were 
changing with respect to outcome scores at different rates when scores for all study 
covariates were controlled.  Last, there was no significant covariance between the 
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intercept and the years in the study period, which means that, after accounting for all 
study covariates, the rate of decline in each outcome was not different among 
participants with different outcome baseline levels.  
Total Cholesterol.  Table 19a displays the results from the REMs for the 
association between TC and all three the outcomes of interest. With respect to the 
cross-sectional results, there was a statistical significant fixed effect for TC in ADLs, 
which indicates lower TC was associated with significantly more ADL disability. No other 
significant fixed effects were observed for TC in IADLs or grip function, which suggests 
that scores for IADLs and grip function were not significantly associated with TC scores. 
With respect to the longitudinal results, none of the TC-by-time interactions were 
statistically significant which indicated that baseline TC scores did not have a significant 
impact on the rate of decline over time for the measured outcomes.  In this fully 
adjusted model, the explained variance across the physical limitations and disability 
measures was 67%-81% for the ICC (between-person) and 25%-43% for the 1-ICC 
(within-person) values.  
Low-density Lipoprotein Cholesterol. Table 19b displays the results from the 
REMs for the association between LDL-C and the outcomes of interest. When 
examining the cross-sectional results, there was no significant fixed effect for LDL-C on 
any of the outcomes, which indicated that scores for physical function measures were 
not significantly associated with LDL-C scores. None of the interactions by time were 
statistically significant which indicated that baseline LDL-C measures were not 
significantly associated with rate of change in the physical function outcomes. In this 
fully adjusted model, the explained variance across the physical limitations and disability 
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measures was 68%-79% for the ICC (between-person) and 24%-43% for the 1-ICC 
(within-person) values.  
 
 
Table 19a. Random Effect Models for all Outcomes and Total Cholesterol.  
 ADLs IADLs Grip 
FIXED EFFECTS     b  SE     b  SE     b  SE 
Intercept  4.29*** 0.32  3.78*** 0.25 39.14*** 0.80 
Time  0.08 0.22 -0.08 0.19  -1.07 0.69 
TC -0.16*** 0.04 -0.05 0.03   0.07 0.10 
TC*Time -0.0002 0.03  0.01 0.02   0.17 0.09 
       
RANDOM EFFECTS       
Variance of the intercept  3.01*** 0.21  1.41*** 0.14 15.87*** 1.08 
Variance of time  0.44*** 0.10  0.31*** 0.07   8.43*** 0.71 
Covariance of intercept, time  0.15 0.11  0.11 0.13   0.04 0.06 
Residual variance  2.75*** 0.11  2.26*** 0.09 14.38*** 0.56 
-2 log likelihood 22941.8   21144.7  29247.6 
 
Note: *p<.05; **p<.01; ***p<.001; TC=Total cholesterol; Values based on SAS PROC Mixed. Entries show 
parameter estimates (b) with standard errors (SE). Estimation Method = ML. Model adjusting for age, sex, 
education, perceived economic situation, hypertension, cholesterol medications, HbA1c, smoking, exercise, 
coronary heart disease, stroke, arthritis, osteoporosis, pulmonary problems, cancer, psychiatric/depression, 
Insomnia, cognitive disability. 
 
Table 19b. Random Effect Models for all Outcomes and Low-density Lipoprotein 
Cholesterol.  
 ADLs IADLs Grip 
FIXED EFFECTS     b  SE     b  SE     b  SE 
Intercept  4.38*** 0.32  3.77*** 0.25 38.92*** 0.80 
Time  0.04 0.22 -0.11 0.20  -1.20 0.69 
LDL-C  0.001 0.002 -0.001 0.001   0.002 0.004 
LDL-C*Time -0.001 0.001  0.0001 0.001   0.001 0.003 
       
RANDOM EFFECTS       
Variance of the intercept  3.01*** 0.20  1.42*** 0.14 15.68*** 1.09 
Variance of time  0.44*** 0.10  0.30*** 0.07   8.59*** 0.72 
Covariance of intercept, time  0.15 0.11  0.12 0.14   0.03 0.06 
Residual variance  2.75*** 0.11  2.28*** 0.09 14.47*** 0.57 
-2 log likelihood 22941.8   20841.6  29298.0 
 
Note: *p<.05; **p<.01; ***p<.001; LDL-C=Low-density lipoprotein cholesterol; Values based on SAS PROC 
Mixed. Entries show parameter estimates (b) with standard errors (SE). Estimation Method = ML. Model 
adjusting for age, sex, education, perceived economic situation, hypertension, cholesterol medications, 
HbA1c, smoking, exercise, coronary heart disease, stroke, arthritis, osteoporosis, pulmonary problems, 
cancer, psychiatric/depression, Insomnia, cognitive disability. 
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Triglycerides. Table 19c displays the results from the REMs for the association 
between TG and all three outcomes of interest. Regarding the cross-sectional results, 
there was a significant positive fixed effect for grip function, which indicates that higher 
TG scores were associated with significantly better grip function. No other significant 
cross-sectional effects were observed for TG in disability, which suggests that scores 
for disability were not significantly associated with baseline TG scores. In regards to the 
longitudinal results, none of the TG-by-time interactions were statistically significant, 
which indicated that baseline TG scores were not significantly associated with rate of 
change in the measured outcomes. In this fully adjusted model, the explained variance 
across the physical limitations and disability measures was 66%-79% for the ICC 
(between-person) and 25%-43% for the 1-ICC (within-person) values.  
 
 
Table 19c. Random Effect Models for all Outcomes and Triglycerides.  
 ADLs IADLs Grip 
FIXED EFFECTS    b  SE    b  SE     b  SE 
Intercept  4.29*** 0.32  3.75*** 0.25 39.18*** 0.80 
Time  0.06 0.22 -0.08 0.19  -1.13 0.69 
TG -0.02 0.06 -0.04 0.04   0.26* 0.13 
TG*Time -0.01 0.04  0.003 0.03   0.08 0.11 
       
RANDOM EFFECTS       
Variance of the intercept  3.04*** 0.21  1.41*** 0.13 15.79*** 1.07 
Variance of time  0.44*** 0.10  0.31*** 0.07   8.48*** 0.71 
Covariance of intercept, time  0.15 0.11  0.11 0.13   0.03 0.06 
Residual variance  2.75*** 0.11  2.26*** 0.09 14.38*** 0.57 
-2 log likelihood 22948.2   21135.6  29232.5 
       
 
Note: *p<.05; **p<.01; ***p<.001; TG=Triglycerides; Values based on SAS PROC Mixed. Entries show 
parameter estimates (b) with standard errors (SE). Estimation Method = ML. Model adjusting for age, sex, 
education, perceived economic situation, hypertension, cholesterol medications, HbA1c, smoking, exercise, 
coronary heart disease, stroke, arthritis, osteoporosis, pulmonary problems, cancer, psychiatric/depression, 
Insomnia, cognitive disability. 
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High-density Lipoprotein Cholesterol. Table 19d displays the results from the 
REMs for the association between HDL-C and the outcomes of interest. With respect to 
the cross-sectional results, there was a statistical significant fixed effect for HDL-C in 
ADLs, which indicates that lower HDL-C scores were associated with significantly more 
ADL disability. No other significant fixed effects were observed for HDL-C in IADLS or 
grip function, which suggests that scores for IADLs and grip function were not 
significantly associated with HDL-C scores. With regard to the longitudinal results, none 
of the HDL-C-by-time interactions were statistically significant, which indicated that 
baseline HDL-C scores were not significantly associated with rate of change in the 
measured outcomes. In this fully adjusted model, the explained variance across the 
physical limitations and disability measures was 68%-81% for the ICC (between-person) 
and 25%-43% for the 1-ICC (within-person) values.  
 
 
Table 19d. Random Effect Models for all Outcomes and High-density Lipoprotein 
Cholesterol.  
 ADLs IADLs Grip 
FIXED EFFECTS    b  SE    b  SE     b  SE 
Intercept  4.27*** 0.32  3.77*** 0.25 39.04*** 0.80 
Time  0.07 0.11 -0.08 0.19  -1.12 0.69 
HDL-C -0.44** 0.16 -0.06 0.12  -0.31 0.38 
HDL-C*Time  0.10 0.11  0.02 0.09   0.23 0.33 
       
RANDOM EFFECTS       
Variance of the intercept 3.03*** 0.21 1.41*** 0.13 15.88*** 1.08 
Variance of time 0.41*** 0.10 0.31*** 0.07   8.48*** 0.71 
Covariance of intercept, time 0.15 0.11 0.11 0.13   0.04 0.06 
Residual variance 2.75*** 0.11 2.26*** 0.09 14.39*** 0.57 
-2 log likelihood 22937.3 21134.6   29566 
 
Note: *p<.05; **p<.01; ***p<.001; HDL-C=High density-lipoprotein cholesterol; Values based on SAS PROC 
Mixed. Entries show parameter estimates (b) with standard errors (SE). Estimation Method = ML. Model 
adjusting for age, sex, education, perceived economic situation, hypertension, cholesterol medications, 
HbA1c, smoking, exercise, coronary heart disease, stroke, arthritis, osteoporosis, pulmonary problems, 
cancer, psychiatric/depression, Insomnia, cognitive disability. 
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Interactions 
In order to examine the second aim of the study, which was to examine whether 
the previous significant lipid associations with their respective outcomes were 
moderated by sex or cognitive disability, REM models were carried out with additional 
interaction terms. To assess moderation on the cross-sectional associations, separate 
two-way-interaction terms were included (e.g. sex*lipid, cognitive disability*lipid). 
Furthermore, to examine whether the association between the lipoprotein and the 
outcomes was moderated by sex or cognitive disability across the three study waves, 
the REM model included three-way interaction terms (e.g. sex*lipid*time, cognitive 
disability*lipid*time).  
Total Cholesterol. Tables 20a and 20b present the models testing the 
moderation of sex and cognitive disability on the relationship between lower TC and 
greater ADL disability. With respect to the cross-sectional results, there was no 
statistical significant moderation by sex. However, cognitive disability did moderate the 
association between TC and ADLs. With regard to the longitudinal results, none of the 
sex or cognitive disability interactions were statistically significant, which indicated that 
the association between baseline TC scores and the rate of ADL decline over time was 
not moderated by sex or cognitive disability. 
Triglycerides. Tables 21a and 21b present the models testing the moderation of 
sex and cognitive disability on the relationship between TG and grip function. There was 
no statistical significant moderation by sex or cognitive disability for either the cross-
sectional or the longitudinal associations between higher TG and better grip function.  
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Table 20a. Models for Moderation of Sex on the Association between TC and Activities 
of Daily Living.  
ADLs 
FIXED EFFECTS b SE 
Intercept 4.29*** 0.32 
Time 0.08 0.22 
TC -0.16*** 0.04 
TC*Sex -0.01 0.04 
TC*Sex*Time -0.006 0.03 
   
RANDOM EFFECTS   
Variance of the intercept 3.02*** 0.20 
Variance of time 0.44*** 0.10 
Covariance of intercept, time 0.15 0.11 
Residual variance 2.75*** 0.11 
-2 log likelihood 22941.5 
 
Note: *p<.05; **p<.01; ***p<.001; ADLs= Activities of Daily Living; TC=Total cholesterol. Values based on SAS 
PROC Mixed. Entries show parameter estimates (b) with standard errors (SE). Estimation Method = ML; Model 
adjusting for age, sex, education, perceived economic situation, hypertension, cholesterol medications, HbA1c, 
smoking, exercise, coronary heart disease, stroke, arthritis, osteoporosis, pulmonary problems, cancer, 
psychiatric/depression, Insomnia, cognitive disability. 
Table 20b. Models for Moderation of Sex and Cognitive Disability on the Association 
between TC and Activities of Daily Living.  
ADLs 
FIXED EFFECTS b SE 
Intercept 4.27*** 0.31 
Time 0.08 0.22 
TC -0.08 0.04 
TC*Cognitive Disability -0.40*** 0.09 
TC*Cognitive Disability*Time 0.14 0.08 
   
RANDOM EFFECTS   
Variance of the intercept 2.94*** 0.20 
Variance of time 0.44*** 0.10 
Covariance of intercept, time 0.16 0.11 
Residual variance 2.75*** 0.11 
-2 log likelihood 22922.1 
 
Note: *p<.05; **p<.01; ***p<.001; ADLs= Activities of Daily Living; TC=Total cholesterol. Values based on SAS 
PROC Mixed. Entries show parameter estimates (b) with standard errors (SE). Estimation Method = ML; Model 
adjusting for age, sex, education, perceived economic situation, hypertension, cholesterol medications, HbA1c, 
smoking, exercise, coronary heart disease, stroke, arthritis, osteoporosis, pulmonary problems, cancer, 
psychiatric/depression, Insomnia, cognitive disability. 
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Table 21a. Models for Moderation of Sex on the Association between TG and Grip 
Function.  
Grip 
FIXED EFFECTS b SE 
Intercept 20.59*** 0.77 
Time 1.25 0.68 
TG 0.26* 0.13 
TG*Sex 0.13 0.12 
TG*Sex*Time 0.09 0.11 
   
RANDOM EFFECTS   
Variance of the intercept 15.77*** 1.07 
Variance of time 8.47*** 0.71 
Covariance of intercept, time 0.03 0.06 
Residual variance 14.38*** 0.56 
-2 log likelihood 29229.8 
 
Note: *p<.05; **p<.01; ***p<.001; TG=Triglycerides. Values based on SAS PROC Mixed. Entries show parameter 
estimates (b) with standard errors (SE). Estimation Method = ML; Model adjusting for age, sex, education, 
perceived economic situation, hypertension, cholesterol medications, HbA1c, smoking, exercise, coronary heart 
disease, stroke, arthritis, osteoporosis, pulmonary problems, cancer, psychiatric/depression, Insomnia, cognitive 
disability. 
Table 21b. Models for Moderation of Cognitive Disability on the Association 
between TG and Grip Function.  
Grip 
FIXED EFFECTS b SE 
Intercept 20.53*** 0.77 
Time 1.30 0.68 
TG 0.18 0.14 
TG*Cognitive Disability 0.54 0.32 
TG*Cognitive Disability*Time -0.28 0.28 
   
RANDOM EFFECTS   
Variance of the intercept 15.77*** 1.07 
Variance of time 8.45*** 0.71 
Covariance of intercept, time 0.04 0.06 
Residual variance 14.37*** 0.56 
-2 log likelihood 29229.6 
 
Note: *p<.05; **p<.01; ***p<.001; TG=Triglycerides. Values based on SAS PROC Mixed. Entries show 
parameter estimates (b) with standard errors (SE). Estimation Method = ML; Model adjusting for age, sex, 
education, perceived economic situation, hypertension, cholesterol medications, HbA1c, smoking, exercise, 
coronary heart disease, stroke, arthritis, osteoporosis, pulmonary problems, cancer, psychiatric/depression, 
Insomnia, cognitive disability. 
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High-density Lipoprotein Cholesterol. Tables 22a and 22b display the results 
of the models testing the moderation of sex and cognitive disability on the relationship 
between HDL-C and ADLs. None of the cross sectional or longitudinal interactions were 
statistically significant for any of the moderators. This indicated that the significant 
cross-sectional association between lower HDL-C and more ADL disability was not 
dependent on sex or cognitive disability.  
 
 
Table 22a. Models for Moderation of Sex on the Association between HDL-C and 
Activities of Daily Living.  
ADLs 
FIXED EFFECTS b SE 
Intercept 4.24*** 0.32 
Time 0.06 0.22 
HDL-C -0.49** 0.16 
HDL-C*Sex -0.21 0.16 
HDL-C*Sex*Time -0.11 0.11 
   
RANDOM EFFECTS    
Variance of the intercept 3.03*** 0.20 
Variance of time 0.44*** 0.10 
Covariance of intercept, time 0.15 0.11 
Residual variance 2.75*** 0.11 
-2 log likelihood 22932.8 
 
 
Note: *p<.05; **p<.01; ***p<.001; ADLs=Activities of Daily Living; HDL-C=High-density lipoprotein cholesterol. 
Values based on SAS PROC Mixed. Entries show parameter estimates (b) with standard errors (SE). Estimation 
Method = ML; Model adjusting for age, sex, education, perceived economic situation, hypertension, cholesterol 
medications, HbA1c, smoking, exercise, coronary heart disease, stroke, arthritis, osteoporosis, pulmonary 
problems, cancer, psychiatric/depression, Insomnia, cognitive disability. 
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Stratification 
Since cognitive disability moderated the association between ADLs and TC, 
stratification by cognitive disability was carried out. There were 1725 subjects without 
cognitive disability and 474 with cognitive disability in this analysis. The mean age for 
those without cognitive disability was 74.8 (SD=8.3) and for those cognitively disabled 
was 85.9 (SD=10.0). Table 23 presents the lipid distribution by cognitive status. Overall, 
participants with cognitive disability had lower lipid levels (all p’s<.001). Table 24 
presents the stratification of the mixed effects models that were carried out to determine 
if the association between ADL disability and TC for participants with and without 
cognitive disability differed. The relationship between low TC scores and more ADL 
disability was only significant for the cross-sectional association on participants with 
Table 22b. Models for Moderation of Sex and Cognitive Disability on the Association 
between HDL-C and Activities of Daily Living.  
ADLs 
FIXED EFFECTS b SE 
Intercept 4.27*** 0.32 
Time 0.06 0.22 
HDL-C -0.46** 0.17 
HDL-C*Cognitive Disability 0.13 0.34 
HDL-C*Cognitive Disability*Time -0.29 0.28 
   
RANDOM EFFECTS   
Variance of the intercept 3.04*** 0.20 
Variance of time 0.44*** 0.10 
Covariance of intercept, time 0.15 0.11 
Residual variance 2.75*** 0.11 
-2 log likelihood 22936.2 
 
Note: *p<.05; **p<.01; ***p<.001; ADLs=Activities of Daily Living; TC=Total cholesterol. Values based on SAS 
PROC Mixed. Entries show parameter estimates (b) with standard errors (SE). Estimation Method = ML; Model 
adjusting for age, sex, education, perceived economic situation, hypertension, cholesterol medications, HbA1c, 
smoking, exercise, coronary heart disease, stroke, arthritis, osteoporosis, pulmonary problems, cancer, 
psychiatric/depression, Insomnia, cognitive disability.  
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cognitive disability, but not the longitudinal association. In other words, at baseline, low 
TC scores were related to greater ADL disability mainly in the presence of cognitive 
disability. 
 
 
 
 
Table 23. Frequency Distribution of Lipoproteins by Cognitive Status. 
 TC LDL-C TG HDL-C 
 Means in mmol/l (SD) 
No Cognitive disability  5.59 (8.3) 9.68 (29.5) 1.83 (1.0) 1.15 (0.33) 
Cognitive disability 5.31 (1.3) 6.80 (20.8) 1.61 (0.9) 1.19 (0.4) 
Note: TC=total cholesterol; LDL=low-density lipoprotein cholesterol; TG=triglycerides; HDL-C= high-density 
lipoprotein cholesterol; mmol/l=millimole per liter SD=Standard deviation. 
 
 
Table 24. Models Stratifying by Cognitive Disability the Association between TC and 
Activities of Daily Living. 
 
ADLs for No 
Cognitive Disability 
 
ADLs for Cognitive 
Disability 
FIXED EFFECTS b SE  b SE 
Intercept 1.72*** 0.33  5.37** 1.82 
Time -0.05 0.03  -0.22 1.29 
TC -0.05 0.03  -0.47** 0.15 
TC*time -0.02 0.03  0.12 0.11 
      
RANDOM EFFECTS      
Variance of the intercept 1.26*** 0.12  9.76*** 1.29 
Variance of time 0.60*** 0.07  0.34 0.57 
Covariance of intercept, time 0.18 0.09  -0.11 0.31 
Residual variance 1.73*** 0.07  6.07*** 0.69 
-2 log likelihood 17278.1  4476.2 
 
Note: *p<.05; **p<.01; ***p<.001.TC=Total cholesterol. Values based on SAS PROC Mixed. Entries show 
parameter estimates (b) with standard errors (SE). Estimation Method = ML; Model adjusting for age, sex, 
education, perceived economic situation, hypertension, cholesterol medications, HbA1c, smoking, exercise, 
coronary heart disease, stroke, arthritis, osteoporosis, pulmonary problems, cancer, psychiatric/depression, 
Insomnia, cognitive disability. 
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Discussion 
 
The present study examined the longitudinal association between physical 
function and TC, LDL-C, TG and HDL-C taking into account demographics, 
cardiovascular risk factors and comorbidity inclusive of cognitive disability in adults over 
the age of 60 participating in the CRELES study. Physical function was measured as 
disability and functional limitations. In this population sample, it was found that there 
was a cross-sectional association between lower TC, and lower HDL-C scores 
specifically, and higher ADL disability after adjusting for all covariates. These findings 
are partly supportive of previous research studies evaluating comparable outcomes 
44,86,87,137,157,158,234.  
Canavan and colleagues looked at the cross-sectional association between both 
vascular risk factors and established cardiovascular diseases and disability in 
community-dwelling adults from West Ireland and also found that older adults with lower 
levels of HDL-C had more functional impairment even after full adjustment for 
demographics, cardiovascular risk factors and comorbidity 86. Furthermore, results from 
the NonaSantfeliu Study in Spain studying the association between HDL-C and physical 
and cognitive performance in adults over the age of 90 with a low level of education 
showed a 1.03 times better ADL performance in those with normal baseline HDL-C 
(p<.006) 137. A study performed in institutionalized older adults also described severe 
disability associated with low levels of TC and HDL-C 157. Moreover, Landi and 
colleagues (2007) examined older adults from the ilSIRENTE study and reported that 
higher HDL-C levels were associated with better physical performance. These results 
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support the study findings and suggest that maintaining optimal HDL-C levels into very 
old age may be protective of physical function. However, contrary associations have 
also been described.  Welmer and colleagues (2014) reported that older adults with high 
TC had more functional dependence; however, this association was no longer 
significant after adjusting for demographics and cardiovascular risk factors (p=.087).  
Although this study identified significant cross-sectional effects between TC and 
ADL disability, it did not identify any longitudinal effects, whereby changes in the 
functional outcomes would be a function of baseline lipoprotein scores. Nevertheless, a 
study from the Longitudinal Aging Study Amsterdam (LASA) did describe time effects. 
Their study assessed the association between TC and a 3-year decline in performance 
and found that older women with lower baseline TC levels had 11.1% more functional 
decline than those with higher TC; however, not among males 44.  
Previous research has reported using hand grip strength as a reliable and valid 
proxy for muscle strength 158 and also as a health and/or disability predictor 275-277. The 
current study found that older adults with higher levels of TG performed significantly 
better in grip strength function. These results are in conflict with those found in a 
population based sample from the Hertfordshire Cohort Study where higher fasting TG 
yielded a 0.5 standard deviation decrease in grip strength after adjusting for covariates 
278. Similar findings were observed by a very recent study conducted on data collected 
between 2002 and 2009 among older Japanese men and women where no grip 
strength associations were observed for those with elevated TGs 276. In the current 
study, no other significant associations were found between the other lipoproteins (e.g. 
TC, LDL-C, and HDL-C) and grip strength. However, this lack of association disagrees 
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with other recent studies who have observed significant associations between 
decreased levels of TC in males with lower grip strength 279, or low HDL-C levels 
associated with declines in grip strength 276.  
There were no additional associations observed between lipoproteins and 
physical function among older Latino adults in this study. One possible explanation for 
the lack of associations may perhaps be an over-adjustment of the models. All clinically 
variables related to dyslipidemia and disability were taken into account without 
discriminating variables that may have been confounds versus those that may have 
been collinear with the lipoprotein measures. Although the full model had the best fit, 
inclusion of potential mediators at level-1 could be considered over-adjustment 280. 
Another possibility may be the origin of the data. Costa Rica ranks among the top 
countries in Latin America on longevity 281 and the country’s health status is often 
compared to that of developed nations. Additionally, the CRELES study sampled 100% 
of older adults over the age of 95 from the Nicoya area, a north-western region of Costa 
Rica globally known for exceptional longevity, also known as a blue zone 282. Nicoyans, 
specifically males, have lower cardiovascular risk markers and less disabilities than their 
counterparts in other areas of the country 283. This perhaps, may have influence the 
overall analysis and caused an underestimate of the associations sought.  
When sex and cognitive disability were tested as moderators in the significant 
associations between lipoproteins and physical function, only cognitive disability had a 
two-way interaction between lower levels of TC and ADL disability. Stratification by 
cognitive status showed that the association between lower levels of TC and more ADL 
disability was only significant for those with cognitive disability. It has been theorized 
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that oxidized cholesterol is the driving force behind the development of cognitive 
problems. This is a reasonable theory providing the brain’s lipid content is high and thus 
very vulnerable to oxidation by free radicals. A recent review of the literature describes 
how despite pathological advancements, it is still unclear whether the oxidative stress is 
the cause or the consequence of dementia; furthermore other proposed causal 
mechanisms for the association between TC and cognitive disability such as 
inflammation cannot be ruled out 284.  
However, the literature has been consistent in reporting cognitive disability 
associated with the disablement process among older adults. Cognitive decline and/or 
impairment are highly correlated with functional decline 14,258,259. A recent study among 
older South Koreans participating in the Suwon Longitudinal Aging Study (SLAS) tested 
whether cognitive disability was associated with the rate of change in physical functional 
status (inclusive of ADLs) and found that older adults with cognitive disability were 0.6 
times more likely to have a disability at baseline and 1.4 times more likely to have a 
disability at year 2 even after adjusting for potential confounders 258. However, 
contradicting reports have been published regarding the association between TC and 
cognitive disability and/or dementia. Many agree that lower TC levels are associated 
with cognitive decline and higher risk of dementia in older adults 124,161,285. A recent 
meta-analysis showed inconsistent results among the studies analyzed; although 3 out 
of the 5 studies looking at TC and cognitive decline found no association, 2 of the 5 
studies reviewed did find high levels of TC associated with a reduced risk of cognitive 
decline 136. To the author’s knowledge, no other study has reported the moderating 
effect of cognitive disability on the association between TC and ADL disability. 
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This study examined the association between lipids and physical function in a 
population study of older Latino adults participating in CRELES. The study covered 59% 
of the Costa Rican territory, making it generalizable for the entire population of Costa 
Rican older adults. Despite the robustness of a population study, several limitations 
need be mentioned. First of all, given the nature of the study, extrapolation of results 
outside the country may be limited.  The Costa Rican economy ranks in the average 
range compared to other Latin American countries, many social determinants of health 
places the country among the highest in the continent 286 possibly hampering 
comparability with Latin countries with lower economies.  A recent study compared the 
association between several cardiovascular risk factors such as lipids, with education (a 
proxy for SES) among older adults participating in the CRELES and the US National 
Health and Nutrition Examination Survey (NHANES) and found little evidence for the 
association; suggesting that the biological underpinnings of CVD risk factors rests 
beyond racial and SES factors 287. Crimmins and colleagues 96 examined biological risk 
profiles by race, ethnicity and nativity among adults over the age of 40 from the National 
Health and Nutrition Examination Surveys (1999-2002) from the United States and 
found that although US Hispanics had higher average biological risk indicator scores 
(including metabolic risk factors such as TC, HDL-C, and glycated hemoglobin) than 
non-Hispanic Whites, once socioeconomic status (SES) was accounted for in the 
models, their high-risk levels in biological systems did not differ. This suggests that if 
SES is properly accounted for in other studies, comparison across cultures may be 
somewhat valid.  
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In addition, lipoprotein levels may be reflective of certain dietary patterns not 
accounted for in this analysis. Lipids were only measured at baseline and this may have 
underestimated the association between lipids and physical function across time. 
Moreover, lipids accounted for were analyzed in mmol/l; normalizing the values to a z-
score, may have made all the lipid effects on the same outcome more comparable.  
Furthermore, many of the variables used in the analysis are self-reported, so these 
should be interpreted with some caution. Most comorbidity questions asked the 
participant if in the last 2 years they were told by a physician they had a specific 
condition; this may have introduced some recall bias in the data. Another obvious 
limitation is the lack of subclinical cardiovascular disease measures, such as 
radiographic atherosclerotic measures, which may have reflected better the 
cardiovascular status of participants. Additionally, some may find the use of the 
maximum value for grip strength of the dominant hand a limitation. It has been reported 
by some that the mean measure is the most reliable 288. However, the maximum grip 
value has been previously used in population studies 263,289. A recently study measured 
the prognostic value of grip strength and health outcomes across several countries and 
they reported that maximum grip strength was a strong indicator and a moderately 
strong predictor of cardiovascular mortality and incident cardiovascular disease 
respectively across country-income strata 263. A last valid limitation in this study is the 
measurement of cognitive disability. A small number of questions are used to evaluate 
cognition in the CRELES study, which may not fully capture cognitive changes over the 
study period. A quarter of respondents were proxies, which may have affected results 
via inaccurate reporting.  
 110 
This study was able to identify potential specific lipoproteins associated with 
physical function in an older Latino population, although lipoprotein scores did not 
appear to be associated with change in function over the three measurements. 
Furthermore, TC seemed to be of particular importance among people with cognitive 
disability. Further aging research should focus in understanding lipid metabolism in 
aging populations and its implications in maintaining physical function as means of 
sustaining independence and a high quality of life. Studying the association of 
lipoproteins, cardiovascular risk factors and comorbidity with physical function in older 
adults for longer periods of time may better determine a causal association. Future 
studies ought to consider analyzing the association between lipoproteins and physical 
function with cardiovascular risk factors and comorbidity as composite covariate scores. 
Research shows that when health factors are aggregated in the old, these are more 
indicative of physical disability 13,87,264. The Zutphen Elderly Study from Netherlands, 
used an aggregate of cardiovascular risk factors (BMI, smoking status, hypertension, 
serum TC and diabetes) in older adults living in the community and found that a high 
cardiovascular risk score was predictive of functional disability, specifically mobility-
related disability in men 154. Another study among older Chinese also found that the 
odds of disability increased when aggregated vascular risk factors were considered 87. 
Further, Van Peet and colleagues concluded that cardiovascular risk factors even at 
advanced ages are prognostic of functional decline 13. 
Additionally, analyzing physical function in sex-stratified cohorts may be more 
indicative for specific health outcomes given the fact that in general, men’s physical 
function had a very different life trajectory than that of females for older cohorts, 
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especially in developing countries like Costa Rica. Comparing the association of lipids 
and physical function across other Latino populations may better identify the 
heterogeneity of the associations across Latino subpopulations as well as within 
subpopulations.  Often the research has collapsed Latinos populations into one 
category, such an approach may underestimate unique mechanisms that may explain 
associations.  Future interventional approaches should be designed to adequately 
address physical functioning limitations across all Latino groups. In addition, further 
molecular and/or cell biological studies should look into the overall metabolic changes 
that are happening from mid to older ages, which are responsible for the underlying 
association between lipoproteins and health outcomes.  
As the population continues to age and the demographic shift becomes more 
evident, finding ways to prevent or postpone disability becomes imperative. If the 
positive association between high TC and HDL-C and better physical function found in 
this study is replicated in intervention trials treating cardiovascular risk factors, lipids 
may become an easy predictive marker of functional health for aging cohorts and 
especially for those with cognitive disability. Lipoproteins along with cardiovascular risk 
factors may become easily accessible modifiable targets to help compress morbidity, 
decrease healthcare burden and slow functional decline for future aging populations. 
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CHAPTER 4: GENERAL DISCUSSION OF LIPOPROTEINS AND HEALTH 
OUTCOMES 
 
Cardiovascular, cognitive and functional health remains major determinants of 
quality of life for aging populations. These health domains often coexist leading to 
disability and to what is refer to as geriatric syndrome 290. Despite important declines in 
mortality from CVD in the last decades, the burden of disease remains high, especially 
for older adults 56. Dyslipidemia is an important risk factor for cardiovascular disease 
and recent research lean towards an influence in mobility as well. This dissertation was 
conducted with the purpose of addressing the possible relationships between 
lipoproteins and cognitive and physical function among older adults using two 
secondary data sets from populations in which these issues had not been addressed. 
This chapter summarizes the main findings of the two studies with a brief discussion. In 
addition, limitations of the dissertation and future directions are addressed. 
The first study addressed the association between lipoproteins, TC, LDL-C, TG 
and HDL-C and cognitive function among older cognitively normal adults from the 
Czech Republic. This study offered novel information in several aspects. First, it 
addressed cognitive function through a composite cognitive score as well as accounting 
for individual cognitive domains. Second, it described sex difference in the mentioned 
associations, which allowed for identification of significant observations that would have 
not been otherwise known. Third, cognitive function studies are scarce among older 
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adults, most of the literature focuses on cognitive decline or dementia. Findings of this 
first study showed significantly better cognitive function among older adults with high 
HDL-C and lower TG levels. Furthermore, older adults with higher levels of HDL-C 
performed better in visuospatial function and attention and working memory tests. 
Moreover, when APOE ε4 allele was accounted for in the statistical models, high levels 
of HDL-C remained significantly associated with composite cognitive measures, 
visuospatial function and attention and working memory. These results are consistent 
with previous studies accounting for TG 210 211 85 and HDL-C 49,85,127,137,213, even after 
adjusting for APOE ε4 allele 45,48,85,165. Further interaction analysis indicated APOE ε4 
allele as a moderator in the above-mentioned associations. DeFrias and colleagues 
(2007) similarly observed that TG moderated the effect of the APOE ε4 allele on the 
memory of older adults. Furthermore, stratification analysis in the current study by 
carriers and non-carriers of the gene revealed that the associations were only significant 
for carriers of the APOE ε4 allele. Further genetic analyses are needed to explore these 
interactions. 
Based on the health-related quality of life conceptual model of Wilson and Cleary 
(1985), additional determinants of health must be addressed as to further evaluate the 
association between lipoproteins and the overall health of the older adult. Social 
determinants of health such as cultural or social and economic factors seem to play a 
major role in the associations with CVD 291. Older Latinos are one of the fastest growing 
minority in the United States and in all Latin America. Thus, it is important to understand 
the association between lipids and health outcomes across diverse Latino 
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subpopulations, such as the older native Latino populations to examine whether similar 
underlying mechanisms account for risk of disability across these subpopulations.  
Therefore, the second study of this dissertation examined the association 
between lipoproteins and physical function among older Latinos. This study used a 
population dataset of older adults residing in Costa Rica. Results showed lower levels of 
TC and HDL-C associated with ADL disability, but not across time. This agrees with 
three previous studies in very different populations 86,137,157,158. Furthermore, this study 
found higher levels of TG related to better left grip function. Interaction analysis 
indicated that cognitive disability moderated the association between TC and ADLs and 
further stratification revealed that the association was only pertinent for participants with 
cognitive disability. Independent of cardiovascular risk factors and an extensive list of 
comorbidities, older Latino adults living in the community with higher levels of TC, TG 
and HDL-C were associated with better physical function outcomes. To the author’s 
knowledge, this was the first known analysis of the association between lipids and 
physical function in a Latino population and the first study to provide the within and 
between-person variances for each of the outcomes, which is important information not 
provided in other studies. 
Serum cholesterol is known to be essential in the aging process for cell division, 
brain and central nervous function as well as for numerous biological immune 
processes 26. However, a buildup of esterified forms of circulating cholesterol, or 
oxidized cholesterol not only forms plaque and vascular disease 292,293 but may also 
lead to cognitive deterioration 284. On the other hand, HDL-C has been known to battle 
oxidation, inflammation, endothelial dysfunction and help modulate the immune function 
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294. Higher levels of HDL-C are not only associated with CVD protection 1,47 but have 
also been associated with better cognitive performance 45,48,49 as well as physical 
function 158. Results found in this dissertation support these previous findings.  
 
Limitations 
Despite the novel aspects of both studies, several limitations ought to be 
addressed. Due to the cross-sectional nature of the first study looking at the association 
between lipoproteins and cognitive function, it is not possible to indicate whether 
lipoproteins relate to change in cognitive functioning. Further, the sample was not 
racially or ethnically diverse and was overall highly educated. Inclusion of some 
caregivers in the analysis cannot be ruled out and this may have introduced a healthy 
bias effect, or the contrary, overloaded caregivers may reflect higher biomarker load. 
The data also lacked some important socio-demographic variables such as income, 
medical comorbidities and medications, which limit the generalizability of the results. 
Plus allocation of the measurement instruments may not fully reflect or encompass each 
specific cognitive domain. Additionally, the timing of biomarkers collection was not ideal 
and thus may not reflect a factual association with cognition. In the second study, 
despite being a representative population longitudinal study, three time points for data 
collection in a five year period may not have been ideal and/or suffice to either observe 
metabolic and functional changes in this older population. In very old cohorts data 
collection may need to be adjusted (narrower windows) in order to decrease reporting 
bias and see more acute associations in the latter part of life. Both studies may also be 
subject to survival and participant bias. The samples may have been selectively 
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healthier than the general population. Last, both studies used secondary data analysis, 
which by nature are subject to a number of inherent limitations such as appropriateness 
of the data and quality issues. 
 
Study Implications 
 Despite the standing limitations in this dissertation, important contributions were 
made to the literature. Both studies showed important associations between similar 
lipoproteins with cognitive and physical outcomes among older adults of very diverse 
backgrounds.  Higher levels of TC and HDL-C yielded healthier outcomes in both 
studies. Maintaining optimal lipids throughout the lifespan may prove to be a compelling 
preventive measure for maintenance of cardiovascular and physical health. Addressing 
these combined health outcomes may support the compression of disability, increased 
the overall quality of life for older adults and may help guide clinicians in predicting 
health decline and prompt age-appropriate interventions to preserve health for as long 
as possible. 
 
Conclusion and Future Directions 
Dyslipidemia is a major cardiovascular disease risk factor that shares some 
pathophysiological pathways between cognitive and physical function. This dissertation 
work was undertaken to assess how lipids are associated to cognitive and physical 
performance in adults over the age of 60. Identifying shared mechanisms of these 
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diseases, such as the important role of TC, TG and HDL-C in both cognitive and 
physical function as seen in this dissertation, may provide the foundation to design 
future age appropriate interventions, optimize clinical care and perhaps in the future 
advocate for policy changes with evidence-based data. Nonetheless, several questions 
beyond the scope of this dissertation remain unanswered. The underlying 
pathways/mechanisms that explain the association between lipoproteins and 
cognitive/functional outcomes remain unclear. Although an interactive concentric model 
of analysis has been proposed as an ideal mechanism to address multifactorial 
conditions in older adults 290, no conceptual model has been designed to assist in the 
development of future studies to identify/elucidate the potential underlying mechanisms. 
However, this might be a beneficial first step to understanding the association. Future 
studies should also try to address these associations in more racially and ethnically 
inclusive populations accounting for additional psychosocial, economical and 
physiological constructs, as well as quality of life measures, which may be mediating 
some of the associations. Including ethnically diverse samples in scientific 
investigations may better validate the associations sought, increase external validity, 
and better address outcome differences/disparities. The question also remains as to 
how high or how low lipoproteins levels should be among different older age groups to 
obtain cognitive and physical function benefits. Future studies should try to address 
these associations using: (a) age groups, (b) quartiles or quintiles of lipid levels and (c) 
quadratic analysis to determine non-linear relationships. Furthermore, studies should 
include common genetic components, such as the APOE gene.  
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